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Γνώσεσθε τήν ἀλήθειαν,
καὶ ἡ ἀλήθεια ἐλευθερώσει ὑμας
You will know the truth, and the truth will set you free
 
– Gospel of  John, chapter 8 verse 32
Κἂν ἒχω προφητείαν 
καὶ εἰδῶ τὰ μυστήρια πάντα καὶ πᾶσαν τὴν γνῶσιν, 
κἂν ἒχω πᾶσαν τὴν πίστιν ὣστε ὂρη μεθιστάνειν, 
ἀγάπην δὲ μὴ ἒχω, ὀυθέν εἰμι 
And if  I have prophetic powers, 
and understand all mysteries and all knowledge, 
and if  I have all faith, so as to remove mountains, 
but have not love, I am nothing
– 1 Corinthians, chapter 13 verse 2
v
AbstrAct
The thyroid gland located in the anterior neck consists of  two main cell types. First, the 
follicular cells that form the functional units, the follicles, in which thyroid hormones are 
produced and stored before release into the blood circulation; second, the parafollicular 
cells or C cells that produce calcitonin, a hormone that takes part in calcium regulation. 
These two cell types can give rise to different forms of  cancer. Understanding basic 
mechanisms that govern the development and differentiation in the embryo may shed 
light on cell-specific mechanisms in tumor development. 
In non-mammalian vertebrates neuroendocrine C cells retain in the ultimobranchial 
glands instead of  being incorporated into the thyroid. Early quail-chick transplantation 
studies indicated that the C cells derive from the neural crest (i.e. are neuroectodermal), 
but this was not confirmed in mammals. In paper I, lineage tracing using a double flu-
orescent reporter (mTmG) showed that thyroid C cells in mouse embryos derive from 
pharyngeal endoderm instead of  the neural crest. It was further shown that endoderm 
markers (Foxa1 and Foxa2) are dynamically regulated in invasive medullary thyroid car-
cinomas in humans. The actual entry of  C cell precursors into the embryonic thyroid 
was investigated in paper II. Immunofluorescence and ultrastructural analysis with trans-
mission electron microscopy indicated that the basement membrane of  the ultimobran-
chial bodies is degraded before fusing with the thyroid primordium and that the process 
required Nkx2-1, a thyroid transcription factor. This suggested that migration and final 
parafollicular positioning of  thyroid C cells is intrinsically regulated during development. 
In paper III, we modified an inducible mouse model of  papillary thyroid cancer (the most 
common type of  thyroid cancer). This mouse model is based on the Cre/loxP-system in 
which a BrafV600E mutation (constitutively activating the MAPK pathway) is conditionally 
activated only in thyroid follicular cells upon induction with tamoxifen. We discovered 
occurrence of  sporadic Cre activity in the absence of  tamoxifen and that microtumors 
developed clonally with functionally normal thyroid follicles side by side. Eventually, 
multifocal papillary thyroid carcinomas of  different phenotypes (classical, tall-cell, hob-
nail, cystic and solid variants) developed within the same gland. Thus, this model enabled 
the detailed study of  different stages in tumor development under conditions that closely 
resemble tumor development in humans. In paper IV, TgCre;BrafV600E mice were recom-
bined with the mTmG reporter to trace mutant cells before overt tumorigenesis. A great 
diversity in proliferation rate among primary GFP-labeled cells that rarely developed into 
microtumors suggested the possibility of  oncogene-induced senescence. Treatment with 
vemurafenib, a specific inhibitor to mutant Braf, inhibited focal tumorigenesis at an early 
stage, suggesting feasibility of  the model in drug testing.
Keywords: Thyroid gland, thyroid cancer, mouse model, developmental biology, lineage 
tracing
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sAmmAnfAttning på svenskA
Sköldkörteln (tyreoidea) är ett hormonproducerande organ på halsen vid struphuvudet. 
Körteln byggs upp av små runda enheter som kallas folliklar och som består av follikelcel-
ler och C-celler. Follikelcellerna producerar sköldkörtelhormon för ämnesomsättningen 
och C-cellerna producerar hormonet calcitonin, som deltar i kroppens kalciumreglering. 
Sköldkörtelns celler har olika embryonala ursprung. Att känna till hur fosterutvecklingen 
går till i detalj är viktigt för att förstå grundläggande egenskaper hos cellerna i ett organ 
men också för att förstå mekanismer som är inblandade i tumörutveckling och som or-
sakar cancer. 
Tidigare trodde man att C-cellerna under fostertiden bildas i den så kallade neurallisten 
varifrån de vandrar till den så kallade gälbågsapparaten i halsen på embryot, för att så 
småningom inkorporeras i sköldkörteln. I avhandlingens första delarbete visas att C-cel-
lerna i själva verket kommer från endodermet, som är ett annat groddblad i embryot. 
Vidare visas att endodermala markörer finns i tumörer (medullär thyroideacancer) som 
bildas från muterade C-celler hos människa. Tumörcellerna återtar således vissa egenska-
per som kännetecknar embryonala celler. I avhandlingens andra arbete ges en detaljerad 
beskrivning av hur C-cellernas förstadier bildas och hur cellerna förvärvar de egenskaper 
som kännetecknar dem normalt och möjligen efter tumöromvandling. Särskilt intresse 
ägnas basalmembranen som förankrar epitelcellerna och under sköldkörtelns utveckling 
utgör barriär mellan de olika celltyperna.
Förutom MTC finns sköldkörtelcancer även av papillär (PTC), follikulär (FTC) och 
anaplastisk typ (ATC). För att cancer ska uppstå krävs genetiska förändringar i en cell på 
ett sätt som leder till att cellen delar sig på ett okontrollerat sätt. Omkring hälften av alla 
patienter med PTC har en specifik mutation (BRAFV600E) som orsakar tumörsjukdo-
men. Med genteknik kan man aktivera just denna mutation i alla follikelceller vilket leder 
till kraftig tumörväxt. Detta skiljer sig dock från det vanliga förloppet hos människa där 
de allra flesta follikelceller saknar mutationen. I avhandlingens tredje delarbete presen-
teras en musmodell där vi visar hur Braf-mutationen kan begränsas till ett mindre antal 
follikelceller, vilket mer ger en mer realistisk modell av tumörutvecklingen hos människa. 
Det fjärde delarbetet utvecklar nämnda musmodell ytterligare och beskriver tidiga skeen-
den i tumörutvecklingen. I detta arbete kombineras musmodellen med en fluorescerande 
reporter där samtliga celler i musen bildar ett protein som lyser rött i fluorescensmikro-
skop. Med samma genteknik som aktiverar mutationen kan cellerna fås att istället bilda 
ett grönt färgämne, vilket gör att de celler som både har bytt färg och aktiverat mutatio-
nen enkelt kan identifieras och tumörer som växer från dessa tumörinitierande celler kan 
studeras redan innan de har gett upphov till egentlig cancer.
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Preface1
”There are only two ways to l ive your l i fe.
One is as though nothing is a miracle.
The other is as though ever ything is a 
miracle”
Alber t Einstein
(1879–1955)
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prefAce
In this thesis I will describe and sum-
marize the scientific work that I have 
done during my time as a PhD student. 
Working with science is a journey that 
often leads you into roads that you 
could not foresee. When I started my 
journey, I had not much of  an idea 
where it would take me. Now 
it is time to sum up and put to-
gether different pieces that form 
a mosaic. The projects described
cover different aspects of  the de-
velopment of  the thyroid gland 
and events that lead to cancer. 
Findings from tracing studies of  
embryonic development and from 
a novel mouse model for studies 
of  papillary thyroid cancer, will 
be presented. The summarizing 
chapters will introduce important 
concepts to the reader and give 
an overview of  the research field. 
Methods that have been used will be 
explained and discussed. Finally, a 
short summary of  the results and con-
clusions of  the entire PhD project will 
be presented. The separate works that 
form the basis of  this thesis are appen-
ded and indexed by Roman numerals.
2 The thyroid gland
”New York, the nation’s
thyroid gland”
Christopher Mor ley 
(1890-1957)
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the thyroid gLAnd
Often resembled to a butterfly, the 
thyroid gland (illustrated in Figure 1) 
is a bilobed gland located in the ante-
rior neck, close to the thyroid cartilage, 
from which it got its name (Wharton, 
1656). The two lobes are connected by 
the isthmus. The thyroid gland produ-
ces several hormones from two distinct 
cell types: the follicular cells (thyrocy-
tes) and the C cells. The follicular cells 
produce mainly the thyroid hormones 
triiodothyronine (T3) and thyroxine 
(T4) and the C cells produce calcitonin 
(Brent, 2012; Copp, 1992). 
2.1 THE THYROID  
FOLLICULAR EPITHELIUM
The follicle is the functional unit of  the 
thyroid and it forms a spherical structu-
re with follicular cells surrounding a 
lumen filled with colloid, see Figure 2. 
The follicular cells are organized in an 
epithelium with the apical side facing 
the lumen and the basal side resting 
on an enveloping basement membrane 
(Santisteban, 2005). This section will 
describe in more detail different fea-
tures of  the thyroid epithelium and its 
important role in producing and sto-
ring thyroid hormones.
 
Fig 1. The thyroid gland (red) in front of  the trachea.
Fig 2. Micrograph of  section from a mouse thyroid 
lobe. Follicles are formed by cells (purple nuclei) that 
surround colloid-filled lumina (pink).
42.1.1 Apical-basolateral polarity and 
cell-cell/matrix interactions
An important feature of  any epithe-
lium is polarity of  the epithelial cells. 
The cell membrane of  an epithelial 
cell can be divided into two distinct 
domains: the apical membrane, facing 
a lumen, and the basolateral membra-
ne facing neighboring cells and the 
circulation (Ericson & Nilsson, 1992; 
Overeem, Bryant, & van Ijzendoorn, 
2015). The two domains are separated 
by tight junctions to form a barrier that 
segregates apical and basolateral pro-
teins and also enables strict control of  
the passage of  different compounds 
between two separated compartments 
(Ojakian, Nelson, & Beck, 1997). In 
the case of  the thyroid, these compart-
ments are the follicle lumen and the 
extrafollicular space. On the apical side 
there are typically microvilli increasing 
the surface (Sauvanet, Wayt, Pelaseyed, 
& Bretscher, 2015). The thyroid epithe-
lium displays all these features of  pola-
rity, exemplified in Figure 3. 
Another difference between the two 
membrane domains is the distribution 
of  membrane-bound receptors and 
other proteins. For example, follicular 
cells receive signals from circulating 
thyroid stimulating hormone (TSH), 
and the TSH receptor is thus located 
in the basolateral membrane (Beau et 
al., 1997).
Cells in an epithelium are polarized not 
only with respect to different plasma 
membrane constituents but also regar-
ding the distribution of  intracellular 
components. For example, the Golgi 
complex is normally located on the 
apical side of  the nucleus (Bornens, 
2008; Ojakian et al., 1997). Also the 
centrosome of  a polarized cell shows 
an apical location, where it organizes 
microtubules, anchoring the apically 
located cilium (Carvajal‐Gonzalez Jose, 
Mulero‐Navarro, & Mlodzik, 2016). In 
paper II, antibodies against proteins 
associated with the Golgi complex and 
with the centrosome were used to mo-
nitor dynamic changes in epithelial po-
larity during embryonic development.
Cell adhesion molecules (CAMs) are 
important in keeping epithelial cells 
closely together and maintaining the 
epithelial integrity (Näthke, Hinck, & 
Nelson, 1993). E-cadherin is a CAM 
that mediates calcium-dependent cell-
cell adhesion and it is generally expres-
sed in epithelia (C. Yoshida & Takeichi, 
1982).  See example of  E-cadherin stai-
The thyroid gland
Fig 3. A thyroid follicle and a part of  its epithelium 
with characteristic features. 
Ctsm=centrosome, TJ=tight junction
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ning in Figure 4. 
The expression of  E-cadherin is lost 
in epithelial-mesenchymal-transition 
(EMT), an event that occurs normally 
during embryonic development, but 
pathologically in tumor progression 
and invasion. EMT is required to re-or-
ganize embryonic cells in the forming 
of  complex tissues, but after reaching 
their final position, epithelial cells 
should be more or less stationary and 
regain their epithelial properties. When 
tumor cells lose their cell-cell adhesion 
and achieve migratory properties in-
volving EMT (Chaffer, San Juan, Lim, 
& Weinberg, 2016), they can infiltrate 
locally, or enter the blood stream and 
metastasize to distant locations in the 
body. This is a hallmark of  malignant 
tumor disease and a strongly negative 
prognostic factor (Guarino, Rubino, & 
Ballabio, 2007). 
Thyroid cells express E-cadherin not 
only in the follicular state but also 
during development (H. Fagman, 
Grände, Edsbagge, Semb, & Nilsson, 
2003). In papers I-III, immunostaining 
for E-cadherin was used to study its 
expression in embryonic development 
and in tumors. 
Cells interact with their neighbors as 
well as with the surrounding matrix. 
The basement membrane (BM) under-
lying all epithelia is the closest layer of  
extracellular matrix (ECM) that provide 
mechanical support and a solid ground 
for the epithelia to rest on. BMs form a 
web of  bioactive ECM proteins such as 
laminin, type IV collagen, nidogen and 
perlecan that influence cell properties 
(Yurchenco, 2011). The presence of  a 
BM is thus important in maintaining 
the apical-basal polarity of  epithelial 
cells. For example, adding BM consti-
tuents on the apical side of  an epithe-
lium can even reverse the polarity of  
the cells (O’Brien et al., 2001). BMs are 
delicate structures that are not visible in 
a light microscope unless some staining 
is used. In paper II immunostaining for 
the BM protein laminin, and electron 
microscopy were used to study the BM
dynamics during embryonic develop-
ment of  the thyroid. See example of  
laminin staining in Figure 4. 
Laminin is a BM protein that forms a 
heterotrimer of  α-, β-, and γ-subunits, 
illustrated in figure 5. The subunits 
form a coil with one end binding to the 
cellular surface and the other end for-
ming three arms that bind to neighbo-
ring laminins and build up a network to 
which other BM constituents assemble 
(Hohenester & Yurchenco, 2013). The 
binding of  laminin to cell surface re-
ceptors, e.g. dystroglycan, is important 
for the establishment of  cell polarity 
and epithelial phenotype (Li, Edgar, 
Fässler, Wadsworth, & Yurchenco, 
Fig 4. Example of  an epithelium surrounding a lu-
men. All epithelial cells express E-cadherin (green) and 
the basal side rests on a basement membrane (red). Cell 
nuclei are blue
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2003). Conversly, impaired or altered 
binding functions of  laminin may pro-
mote EMT and invasiveness (Giannelli, 
Bergamini, Fransvea, Sgarra, & Anton-
aci, 2005; Zeisberg & Neilson, 2009).
2.1.3 Uptake and transport of  iodine
Iodine is a chemical element with atom 
number 53. In its gaseous state it forms 
a purple gas, hence the name from the 
Greek word ἰώδης, meaning ‘purple’. 
Iodine is a relatively scarce element, 
and the ability to concentrate it is the-
refore crucial for all organisms that use 
it for hormone production. Iodide (I-) 
is the reduced form of  iodine that is 
transported and metabolized in cells 
(Wahab, 2009).
To achieve adequate concentrations of  
iodide, the thyroid needs a mechanism 
for iodide uptake, formerly referred 
to as iodide trapping (Wolff, 1964). 
This is provided by the sodium-iodi-
de-symporter (NIS) that is located in 
the basolateral plasma membrane and 
transports iodide into the cell against 
its concentration gradient (Dai, Levy, 
& Carrasco, 1996; Dohán et al., 2003; 
Portulano, Paroder-Belenitsky, & Car-
rasco, 2014). After uptake, iodide is 
transported across the apical cell mem-
brane and released into the colloid. The 
mechanism of  apical I- efflux, which is 
a regulated process (M. Nilsson, Björk-
man, Ekholm, & Ericson, 1990) is not 
fully understood but transporters as 
pendrin and anoctamin are thought to 
contribute (Silviera & Kopp, 2015; A. 
Yoshida et al., 2002).
2.1.2 Thyroid hormone production
The thyroid hormones triiodothyroni-
ne (T3) and thyroxine (T4) are impor-
tant for many metabolic processes in 
the body that include energy expendi-
ture. The numbers 3 and 4 refer to the 
number of  iodine atoms bound to the 
hormone molecule (Gross & Pitt-Riv-
ers, 1953; Harington, 1926).  See Figure 
6 for chemical structure. 
T3 is biologically more active than T4 
and if  there is an increased need of  
thyroid hormone supply, T4 can be pe-
ripherally converted into T3. In target 
cells, thyroid hormones bind to the thy-
roid hormone receptors that activate or 
repress transcription of  a multitude of  
target genes (Brent, 1994). 
The actual thyroid hormone synthe-
sis (illustrated in Figure 7) takes place 
Fig 5. Upper: Laminin, a heterotrimer formed by three 
subunits. Lower: Laminin proteins forming a network 
on a cell surface.
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extracellularly at the apical cell surface 
(Brix, Linke, Tepel, & Herzog, 2001; 
Ekholm, 1981). Thyroglobulin (Tg) 
and thyroperoxidase (TPO) are two 
important proteins in hormone synt-
hesis that unlike NIS are expressed 
exclusively in the thyroid and only in 
follicular cells. Tg is a giant molecule 
(molecular weight around 330 kDa) 
that is synthesized by the follicular cells 
and released into the follicular lumen 
by exocytosis (Di Jeso & Arvan, 2016). 
TPO is a membrane-bound protein 
that iodinates and couples oxidized io-
dine to tyrosine residues on Tg in the 
presence of  hydrogen peroxide (H2O2) 
(Corvilain, Van Sande, Laurent, & Du-
mont, 1991), which is produced by dual 
oxidase 1 and 2 (DuOX1/2), also at 
the apical membrane (Dupuy, Virion, 
Ohayon, Kaniewski, & Pommier, 1991; 
Massart et al., 2011). Monoiodotyrosi-
ne (MIT) and diiodotyrosine (DIT) are 
primarily produced. The coupling of  
MITs and DITs produces triiodothyro-
nine (T3) and thyroxine (T4) (Malthiéry 
et al., 1989). 
Iodinated Tg is stored in the lumen at 
a very high protein concentration, thus 
Fig 7. Synthesis of  thyroid hormones.Tg (thyroglobulin, 
in brown) is produced by a follicular cell and transpor-
ted by exocytosis into follicular lumen. Iodide (purple) 
is transported into the follicular cell by NIS (red) and 
then by an apical transporter (green) into the lumen, 
where it is coupled to tyrosine residues (oval-shaped) on 
Tg to create monoiodotyrosine (MIT) and diiodotyrosi-
ne (MIT). Next, MITs and DITs are combined to cre-
ate thyroid hormones, T3 and T4. Tg is then transported 
back into the cell by endocytosis. MIT, DIT, T3 and T4 
are released from Tg. Iodide from MIT and DIT are 
recycled in hormone synthesis. T3 and T4 are released 
into blood stream by the transporter MCT8 (blue).
Fig 6. Thyroid hormones. 
Upper: triiodotyronin, T3  Lower: thyroxine, T4
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forming the characteristic colloid. The 
follicular cells continuously internalize 
colloid by apical endocytosis to trans-
port Tg into the follicular cell. Internali-
zed Tg is degraded by lysosomal action, 
and T3 and T4 become released into the 
cytoplasm (Rousset et al., 1989). They 
are then available for transport into the 
blood stream that recently was found 
to be actively mediated by the mono-
carboxyl transporter 8, MCT8, located 
at the basal membrane of  the thyroid 
epithelium (Bernal, Guadano-Ferraz, 
& Morte, 2015). Otherwise, MCT8 is 
primarily appreciated for its pivotal role 
in supplying the brain with thyroid hor-
mones required for normal neurogene-
sis; patients with MCT8 inactivating 
mutations suffers from severe neurolo-
gical impairments.
2.1.4 Regulation of  thyroid hormo-
ne, growth and function
Thyroid hormone blood level is ma-
intained by the pituitary gland, which 
releases thyroid stimulating hormone 
(TSH) in response to low levels (Mag-
ner, 1990). TSH has several effects on 
the thyroid. It stimulates the expression 
of  thyroid genes (NIS, TPO, Tg and 
more) and increases NIS-mediated io-
dide uptake, TPO-mediated iodination, 
H2O2 production, and endocytosis of  
Tg. TSH thus stimulates almost all 
functions of  the follicular cells aiming 
to increase thyroid hormone produc-
tion and release. 
Elevated levels of  TSH also have a 
growth stimulating effect on the thyroid 
(Dumont, Lamy, Roger, & Maenhaut, 
1992; T. Kimura et al., 2001). Clinical-
ly, enlargement of  the gland regardless 
of  the underlying reason is designated 
as goiter. Globally, the most common 
cause of  goiter is iodine-deficiency. In 
these cases, the thyroid cannot pro-
duce sufficient amounts of  thyroid 
hormones and this causes elevation 
of  circulating TSH that stimulates 
thyroid cell proliferation, in some ca-
ses with growth of  the gland to very 
large dimensions (Knobel, 2016). The 
mitogenic effect of  TSH is mediated 
by activation of  the cyclic AMP/pro-
tein kinase A pathway (Dremier et al., 
2006). Under physiological conditions 
with normal thyroid hormone levels, 
thyroid cells replicate very slowly (Co-
clet, Foureau, Ketelbant, Galand, & 
Dumont J, 2008; Saad et al., 2006).
TSH stimulation causes morphological 
changes of  the thyroid epithelium un-
related to hyperplasia. In follicles that 
are not active, the epithelium is gene-
rally flat and the lumen is large due to 
retention of  colloid. When cells are 
stimulated by TSH, as a consequence 
of  increased endocytosis, the amount 
of  colloid is gradually reduced. Also, 
changes of  shape make the cells more 
cuboidal. Active and inactive follic-
les can thus be discerned by different 
morphology and ratio between colloid 
and surrounding epithelium (Gérard et 
al., 2002). The follicular structure was 
an important parameter to evaluate in 
the mouse tumor models studied in pa-
pers III and IV.
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Fig 8. Electron micrographs of  C cells. Large arrow in A shows a C cell between two follicular cells. Small 
arrows show electron dense granula in the cytoplasm. Scale bars: 1 µm
2.2 C CELLS
The neuroendocrine cells of  the thy-
roid were first named parafollicular 
cells by Nonidez (Nonidez, 1932) 
and later C cells by Pearse, not as an 
acronym of  their hormonal product, 
but because the follicular cells were 
then called acinar or A cells and the 
endothelial cells of  the thyroid were 
called B cells (Pearse, 1966). Thyroid 
C cells are scattered in the gland with 
predominance in the center of  the 
lobes, reflecting their developmen-
tal origin, which will be discussed in 
detail in another chapter. Most often 
the C cells are found as a part of  the 
follicles, invested by the same BM as 
the follicular cells, but they can also 
give rise to so-called solid cell nests 
(SCN) (Cameselle-Teijeiro et al., 1994; 
Harach, 1987). SCNs are considered 
to be remnants of  the ultimobranchi-
al epithelium from which the C cells 
derive. They can present a diagnostic 
problem since they could be mistaken 
for microcarcinomas and their poten-
tial to malignify has been a matter of  
debate (Manzoni et al., 2015). 
The C cells are often polygonal in 
shape. They can be recognized by their 
expression of  calcitonin, which can be 
easily detected by immunostaining. Ul-
trastructurally, they are characterized 
by the presence of  electron dense gra-
nules in the cytoplasm typical of  neu-
roendocrine cells (Ericson, 1968). 
Calcitonin is a hormone that participa-
tes in regulating the levels of  calcium 
in the body. However, in humans this 
function is redundant to the function 
of  the parathyroid glands and calci-
tonin substitution is not necessary in 
patients who have undergone thyroi-
dectomy (Davey & Findlay, 2013).
Nonetheless, calcitonin is an im-
portant serum marker to confirm a 
conspicuous thyroid carcinoma of  C 
cell origin before the tumor identity is 
determined histologically and to moni-
tor cancer relapse. Experimentally, cal-
citonin is used to differentiate C cells 
from others in both embryonic and 
adult thyroid. Papers I and II of  the 
thesis focused on C cell development 
in mammals using mouse embryos as 
a model.
3 Thyroid 
development
”I’ve always believed in the adage that 
the secret of  eter nal youth is ar rested 
development”
Alice Roosevelt  Longwor th
(1884–1980)
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thyroid deveLopment
Much knowledge about how organs 
develop has come from the studies of  
animal models, such as mouse, chick 
and zebrafish (Castro‐González, Le-
desma‐Carbayo María, Peyriéras, & 
Santos, 2012). These models recapitu-
late to different extent the embryonic 
development in humans. There are also 
studies where human embryos from 
legal abortions are used. Obviously, 
the representativeness of  such studies 
cannot be controlled and they are also 
limited by problems of  availability, not 
to mention the difficult ethical con-
troversies that arise in human embryo 
studies. However, comparative studies 
on organogenesis in human and mou-
se embryos, strongly indicate that the 
developmental processes of  many or-
gans, including the thyroid, are very si-
milar in the two species (Krishnan et 
al., 2014; Trueba et al., 2005; Xue et al., 
2013).
Animal models have thus become im-
portant to perform detailed investiga-
tions of  molecular mechanisms that 
govern embryonic development. They 
also provide opportunities to study 
the effects of  genetic alterations with 
bearing on the understanding of  dys-
genesis leading to congenital malfor-
mations in children. This chapter will 
give an overview of  the embryonic 
development of  the head and neck re-
gion, especially regarding the thyroid 
primordia, and also describe the func-
tion of  some genes that have proven 
important in regulating the develop-
ment of  the thyroid gland (Fernández, 
López-Márquez, & Santisteban, 2014).
3.1  THE PHARYNGEAL 
APPARATUS
The pharyngeal apparatus is formed 
along the anterior part of  the gut tube 
(Frisdal & Trainor Paul, 2014; Graham, 
2003). The pharyngeal arches are 
bulging segmental structures in the me-
senchyme lateral to the gut epithelium. 
See Figure 9 for illustration. The 
arches have a dorso-ventral direction 
and are separated by pharyngeal 
pouches internally, and pharyngeal 
clefts externally. In fish, the branchial 
or gill arches are homologous to the 
pharyngeal arches, and occasionally 
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branchial refers to distinct derivatives 
of  these transient structures. All three 
germ layers (ectoderm, mesoderm 
and endoderm) contribute to the pha-
ryngeal apparatus and different parts 
of  the endoderm are destined to form 
a number of  glands in the developing 
fetus. The developmental course is 
mostly similar in mouse and human, 
but is naturally much more rapid in 
the mouse embryo (Gillam & Kopp, 
2001). Unless otherwise specified, the 
following description will refer to the 
developmental events that are shared in 
mouse and human.
In each pharyngeal arch there is a 
pharyngeal arch artery (PAA) running 
from the aortic sac to the dorsal aorta. 
Similar to the arches and pouches, the 
PAAs are transient vessels that develop 
in cranial to caudal direction and all of  
them are not present at the same time. 
Parts of  them will contribute to defini-
tive vessels in the head and neck region 
(Rana, Sizarov, Christoffels, & Moor-
man, 2014). 
The arches also get contribution of  
cells derived from the neural crest 
(NC). NC cells (NCC) that originally 
emigrate from the neural fold during 
formation of  the neural tube. From 
this location in the dorsal part of  the 
embryo some NCCs colonize the pha-
ryngeal arches. Eventually, they give rise 
to skeleton, connective tissue and ner-
ves (Graham, Begbie, & McGonnell, 
2004). This is why cranial NCCs also 
are named ectomesenchymal referring 
to their (neuro) ectodermal origin. 
The mesodermal parts of  the arch 
mesenchyme end up as muscles and 
contribute to the formation of  pha-
ryngeal vessels (Trainor, Tan, & Tam, 
1994).
Patterning of  the pharyngeal appara-
tus is important in providing the cues 
that determine fates of  organ- and 
tissue-specific cell lineages (Graham, 
2003). In this process, NCCs and the 
gut endoderm act in concert to or-
chestrate the division of  the pharynge-
al apparatus into segments with distinct 
identities and fates (Graham, Okabe, & 
Quinlan, 2005).
The number of  pharyngeal arches 
differs between species. Mammals ge-
nerally have fewer arches than lower 
Fig 9. The pharyngeal apparatus from a dorsal view. 
Roman numerals indicate pharyngeal arches and Ara-
bic numeral indicate pharyngeal pouches (pp). Green co-
lor indicates external layer of  ectoderm. Corresponding 
internal layer in red indicates pharyngeal endoderm.
The midline thyroid (MT) originates at the level of  the 
second arch. Ultimobranchial bodies (UBs) bud form 
from the fourth pouches.
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vertebrates and in mouse and human 
the arches are numbered from I to VI 
(Graham, 2003). The fifth arch forms 
transiently and soon regresses without 
leaving traces in the form of  any defi-
nitive tissues.
Between the arches, pharyngeal 
pouches are found as outpocketings of  
the anterior endoderm. The first pair 
of  pouches grows deeper and nearly 
meets the corresponding clefts, which 
invaginate from the exterior surface of  
the embryo. Only a thin membrane that 
becomes the eardrum will eventually 
separate them first pharyngeal pouch 
and cleft. Thus, the first pouch forms 
the middle ear and the auditory tube, 
retaining its contact with the definitive 
pharynx (Grevellec & Tucker, 2010).
The second pouches harbor the pala-
tine tonsils while the endoderm of  the 
third pouches develop into the parat-
hyroid glands and the thymus. In mice, 
only one pair of  parathyroid glands is 
present, while in humans another pa-
rathyroid pair forms from the fourth 
pouches (Grevellec & Tucker, 2010).
The most distal of  the pouches are of  
special interest in the present work, 
since they are the source of  the ulti-
mobranchial bodies (UBs) (Cordier 
& Haumont, 1980). The human UBs 
form as a part of  the fifth pouch (Gre-
vellec & Tucker, 2010; Kingsbury, 
1915), while the UBs in mice are the 
only derivatives of  the fourth pouches. 
The name of  the ultimobranchial bo-
dies refers to the fact that they come 
from the most posterior (ultimo- means 
last) pharyngeal (or branchial) pouches. 
The UBs are important in thyroid de-
velopment since they bring the C cells 
to the thyroid and in cases where fusi-
on does not occur, no C cells will be 
present in the thyroid. This is opposed 
to in non-mammalian species, in which 
the UBs instead form the ultimobran-
chial glands that contain C cells, being 
anatomically separate from the thyroid 
(Kameda, 2017). 
3.2 BUDDING, MIGRATION 
AND FUSION OF 
THYROID PRIMORDIA
The entire multistep process of  thyroid 
organogenesis, occurs within one week 
in the mouse embryo, corresponding 
to embryonic days (E) 8.5-15.5. The-
reafter, further growth and maturation 
of  the follicular thyroid predominates. 
In humans, thyroid development takes 
nearly two months, between gestation 
weeks 3-10 (or E20-70) to accomplish 
(De Felice & Di Lauro, 2004).
The thyroid primordium develops in 
the midline, at the level of  the second 
arch. It forms from the ventral part 
of  the pharyngeal endoderm, in close 
proximity to the aortic sac. In mice, it 
first appears as a thickening of  the en-
doderm, forming a placode at E8.5, see 
Figure 10. The placode will further on 
Fig 10. The thyroid placode (red cells) forming in the 
pharyngeal endoderm around E8.5 in the mouse em-
bryo.
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enlarge and bulge out to form the thy-
roid bud that eventually looses its con-
nection to the pharyngeal endoderm 
around E10.5, see Figure 11. The bud 
then descends ventrally of  the gut tube 
and lung buds, and reassumes a close 
apposition to the aortic sac, after which 
it expands bilaterally along the third 
PAA (Fagman, Andersson, & Nilsson, 
2006; Rømert & Gauguin, 1973), see 
Figure 12. The close relation to large 
vessels has been suggested to function 
as a guiding track for bilateral growth 
and symmetrical lobe formation (Alt et 
al., 2006; Fagman et al., 2006).  
As mentioned above, the paired UB 
buds off  from the most posterior pha-
ryngeal pouches, and migrate, surroun-
ded by ectomesenchyme to approach 
the midline primordium with which 
it fuses bilaterally around E13.5. The 
thyroid is thus formed by one medial 
and two lateral primordia that bring, re-
spectively, follicular cells and C cells to 
the prospective gland. The fusion pro-
cess and mechanisms regulating it were 
addressed in paper II. 
3.3 EMBRYONIC GROWTH 
AND DIFFERENTIATION
After fusion of  primordia, the two thy-
roid lobes gradually enlarge by forming 
cords radiating from the central parts, 
represented by the UB remnant, see Fi-
gure 13. Recent findings indicate that 
this developmental stage involves bran-
ching morphogenesis under the influ-
ence of  stromal expression of  Fgf10 
(Liang et al., 2018). In contrast to the 
Fig 11. Upper drawings: Thyroid primordia bud from 
the pharyngeal endoderm in a mouse embryo around 
E10.5. The thyroid bud is formed at the level shown in 
Figure 9. The ultimobranchial bodies (UBs) are formed 
from the fourth pharyngeal pouches (pp). 
Lower drawings: Midline thyroid (MT) descends to the 
level of  the UBs after budding, around E11.5 in the 
mouse embryo.
Fig 12. Migration of  thyroid primordia. Transverse se-
ction through an embryo corresponding to E12.5 in the 
mouse. The midline thyroid (MT) is growing bilaterally 
along the same course as the 3rd pharyngeal arch artery 
(PAA).  The relation to the trachea and esophagus 
are shown.
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adult gland, growth of  the embryonic 
thyroid is not dependent on TSH sig-
naling (Postiglione et al., 2002). Figure 
13 shows the thyroid early after fusion.
Functional differentiation of  proge-
nitors is identified by cell-specific ex-
pression of  Tg and calcitonin, starting 
around E15.5. This happens in paral-
lel with folliculogenesis, which leads 
to the formation of  many small func-
tional units where hormone synthesis 
takes place as described above. The 
regulation of  differentiation onset is 
not completely understood. Trancrip-
tion factors that are required for this 
and other stages of  thyroid develop-
ment are discussed in the next section. 
However, it is unclear how their actions 
are timely controlled to avoid precocio-
us differentiation. For example, Nkx2-
1, Hhex and Pax8 are expressed already 
as thyroid progenitors assemble in the 
placode in the pharyngeal floor, but so-
mehow it does not lead to differentia-
tion at such an early stage. The morp-
hogenetic role of  vessels in thyroid 
development has been investigated in 
different ways. Various extrinsic signals 
such as Sonic hedgehog influence bi-
lateral growth of  the midline thyroid 
(Henrik Fagman et al., 2006). It is also 
clear that interactions with endothelial 
cells and basement membranes are im-
portant for the formation of  follicles 
and for their differentiation (Hick et al., 
2013; Villacorte et al., 2016).
Keeping thyroid cells in an undifferen-
tiated state is probably important to 
finish the spatial rearrangements that 
the thyroid primordia undergo before 
folliculogenesis and terminal differen-
tiation commence. The significance of  
a promigratory and undifferentiated 
phenotype has been discussed not only 
for embryonic thyroid progenitors, but 
also for the development of  thyroid 
cancer (Nilsson & Fagman, 2017). 
3.4 GENES PARTICIPATING 
IN THYROID 
DEVELOPMENT
Much knowledge about thyroid deve-
lopment has been achieved through the 
studies of  both wildtype and genetical-
ly engineered mouse embryos (Fernán-
dez et al., 2014). The morphogenetic 
events that lead to the formation of  
a bilobed gland are well characterized, 
but the molecular mechanisms that go-
vern different steps of  development 
are not completely understood. Some 
factors however, are known to be of  
crucial importance. The combined 
expression of  the four transcription 
factors Nkx2-1, Pax8, Foxe1 and Hhex 
Fig 13. The thyroid gland after fusion with the ulti-
mobranchial bodies (UBs), corresponding to E14.5 in 
the mouse. UB remnants are visible as scattered cells 
(green) in the central parts of  the lobes that are about 
to form projections that will grow into cords radiating 
from the centre of  the lobes. The two lobes are connected 
by the isthmus. 
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is unique for the earliest formed progeni-
tors of  the thyroid follicular lineage (Da-
mante, Tell, & Di Lauro, 2001; Pellizzari 
et al., 2000). They do not only work alone 
but also in concert as a regulatory network 
where the factors interact transcriptional-
ly, which complicates the understanding 
of  their individual roles in thyroid deve-
lopment (Parlato et al., 2004). Each of  
these factors will be shortly introduced 
in the following sections, highlighting the 
relevance for the thesis work. The genes 
Foxa1, Foxa2 and Sox17 are not part of  
the  transcriptional signature of  the thy-
roid, but they are introduced here, since 
they play important roles in the work pre-
sented in paper I.
3.4.1 Nkx2-1
Formerly known as TTF-1 (thyroid trans-
cription factor 1), Nkx2-1 is a homeobox 
transcription factor that is expressed in 
both thyroid primordia, and additionally 
in the trachea, lungs and forebrain during 
embryonic development (Lazzaro, Price, 
de Felice, & Di Lauro, 1991). Soon after 
thyroid specification in the pharyngeal 
endoderm, Nkx2-1 can be detected in the 
midline thyroid and also in the UB epithe-
lium. It is important for the survival of  
thyroid progenitors, but since the midline 
thyroid is formed normally in the pha-
ryngeal endoderm even in mice deficient 
of  Nkx2-1, it is not necessary for the ear-
liest stages of  development (S. Kimura, 
Ward, & Minoo, 1999). However, these 
mice are born without a thyroid and die 
at birth due to lung hypoplasia. Nkx2-1 
regulates the expression of  thyroid-speci-
fic genes such as Tg and TPO (Fernández 
et al., 2014) but also stimulates calcitonin 
production by mature C cells (Suzuki, 
Katagiri, Ueda, & Tanaka, 2007). Notably, 
Nkx2-1 has several domains that seem to 
be important for differential transcrip-
tion. This could explain its pleiotropic ac-
tions at different stages of  development 
(Silberschmidt et al., 2011). Immunostai-
ning for Nkx2-1 expression was routinely 
used to identify embryonic thyroid and 
ultimobranchial cells (papers I and II) 
and thyroid tumors (paper III). In view 
of  the fact that Nkx2-1 is required for 
thyroid-UB fusion (Kusakabe, Hoshi, & 
Kimura, 2006), the thyroid phenotype 
in mouse embryos haplosufficient for 
Nkx2-1 was a subject of  study in paper 
II, devoted to UB and C cell developme-
nt.
3.4.2 Pax8
The paired box gene Pax8 is expressed in 
thyroid cells, only in the follicular linea-
ge. Additionally, Pax8 is of  importance 
for development of  a few other organs, 
most notably the kidneys (Mansouri, 
Chowdhury, & Gruss, 1998). In Pax8 
null mice, the midline thyroid is formed, 
but then it regresses and disappears and 
newborns are severely hypothyroid (Par-
lato et al., 2004). Since Pax8 is not ex-
pressed in the UB epithelium, the UBs 
develop in Pax8 knockouts and remain 
in the normal locations for the missing 
thyroid lobes, consisting predominantly 
of  calcitonin-producing cells (Mansou-
ri et al., 1998). Pax8 is also important at 
later stages of  development to control 
differentiation of  follicular cells and to 
prevent apoptosis (Marotta et al., 2014). 
In paper II, staining for Pax8 was used to 
distinguish cells originating from the mid-
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line thyroid from cells originating from 
the UBs, and the UB phenotype was 
studied in Pax8 deficient embryos.
3.4.3 Foxe1 and Hhex
Foxe1 belongs to the forkhead domain 
transcription factor family and was pre-
viously known as thyroid transcription 
factor 2, or TTF-2 (Civitareale, Lonig-
ro, Sinclair, & Di Lauro, 1989; Fernán-
dez et al., 2014). It is widely expressed 
in pharyngeal endoderm, but not in 
the second, third or fourth pharyngeal 
pouches (Dathan, Parlato, Rosica, De 
Felice, & Di Lauro, 2002). Mice defi-
cient of  Foxe1 die shortly after birth by 
failure to thrive due to a cleft palate, 
but they also have a severe thyroid phe-
notype comprising athyreosis, alternati-
vely a remaining, small thyroid remnant 
located under the tongue (De Felice et 
al., 1998). It is suggested that Foxe1 
downstream of  Nkx2-1 and Pax8 dri-
ves migration of  the thyroid primordi-
um after budding is completed (Parlato 
et al., 2004). FOXE1 is also a suscepti-
bility gene in thyroid cancer (Jones et 
al., 2012). 
The hematopoietically expressed ho-
meobox gene Hhex is expressed in the 
embryonic thyroid but also in other 
foregut derivatives as liver, lung and 
thymus (Bedford, Ashworth, Enver, 
& Wiedemann, 1993; Bogue, Ganea, 
Sturm, Ianucci, & Jacobs, 2000). In 
Hhex-/- mice, the midline thyroid is pri-
marily formed and Nkx2-1, Pax8 and 
Foxe1 are initially normally expressed. 
However, these transcription factors 
are soon thereafter downregulated, 
suggesting an important role for Hhex 
in maintaining their expression (Marti-
nez Barbera et al., 2000; Parlato et al., 
2004). Foxe1 and Hhex were not speci-
fically studied in this thesis and will not 
be further discussed.
3.4.4 Foxa1 and Foxa2
There are three members of  the fork-
head box A gene family; Foxa1, Foxa2 
and Foxa3. The first two of  these 
factors cooperate in embryonic de-
velopment and are partly redundant 
(Kaestner, 2010). Foxa2 is ubiquitously 
expressed in the pharyngeal endoderm 
but is downregulated in thyroid proge-
nitors before the thyroid bud is formed 
(Fagman et al., 2011). Both Foxa1 and 
Foxa2 act as pioneer factors, which 
means that they regulate chromatin 
organization and thereby make the 
distinct parts of  the genome available 
for the binding of  other transcription 
factors (Kaestner, 2010). Foxa2 has 
been shown to regulate the calcitonin 
promoter in C cells (Viney et al., 2004). 
The Foxa genes are crucially important 
also for the development of  other or-
gans that derive from foregut endo-
derm, such as lung and liver (Costa, Ka-
linichenko, Holterman, & Wang, 2003; 
Hannenhalli & Kaestner, 2009), which 
makes the thyroid an interesting excep-
tion. In paper I, the expression pattern 
of  Foxa1 and Foxa2 was investigated 
in the UB epithelium and embryonic C 
cells in mouse, and in tumor samples 
of  human medullary thyroid cancer. 
3.4.5 Sox17
There are 20 genes belonging to the 
Sox family comprising SRY (sex-deter-
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mining region of  the Y chromosome) 
–related HMG (high mobility group) 
–containing box genes (Kiefer Julie, 
2007). Sox17 is important for the spe-
cification and formation definitive en-
doderm (Séguin, Draper, Nagy, & Ros-
sant, 2008). It is expressed in the entire 
gut tube of  early mouse embryos, but 
is down-regulated in the foregut endo-
derm around E8.5 (Kanai-Azuma et 
al., 2002). In paper I, tracing the pro-
geny of  endoderm cells that previously 
expressed Sox17 (Engert, Liao, Burt-
scher, & Lickert, 2009) was used to in-
vestigate their contribution to progeni-
tor cells of  the thyroid and UB. 
3.5 THYROID 
DEVELOPMENTAL 
DEFECTS
In humans, significant disturbances 
in thyroid development cause a varie-
ty of  clinical conditions in which thy-
roid function is impaired or even lost. 
Congenital hypothyroidism (CH), is 
a fairly common developmental de-
fect with an incidence around 1/3500 
newborns (Toublanc, 1992). CH can be 
caused by dyshormonogenesis (the in-
ability to produce thyroid hormones), 
accounting for approximately 15 % of  
cases, or thyroid dysgenesis, in which 
impaired organogenesis lead to athyre-
osis (no thyroid is found), hypoplasia 
(the size of  the thyroid is reduced) or 
ectopia (thyroid tissue present at other 
locations than normal), accounting for 
the remaining 85 % of  cases (De Felice 
& Di Lauro, 2004). 
Before birth, maternal thyroid hormo-
nes can compensate for the lack of  en-
dogenous production in the embryo, 
but children that are born with insuf-
ficient ability to produce thyroid hor-
mones will develop symptoms ranging 
from mild hypothyroidism to cretinism, 
characterized by dwarfism and mental 
retardation (Vulsma, Gons, & de Vijl-
der, 1989). Most cases of  CH are spo-
radic. Notably, dysgenesis associated 
with mutations in known thyroid de-
velopmental genes as NKX2-1, PAX8 
and FOXE1 comprise only a minority 
of  cases (De Felice & Di Lauro, 2004; 
Macchia et al., 1998; Nettore, Cacace, 
De Fusco, Colao, & Macchia, 2013). 
Familial clustering exists, and abnor-
mal thyroid function is more common 
in first-degree relatives to children with 
CH, than in controls (Sindhuja, Day-
al, Sodhi, Sachdeva, & Bhattacharya, 
2016), although thyroid dysgenesis is 
often discordant  in monozygotic twins 
(Perry et al., 2002).
Occasionally, thyroid dysgenesis is as-
sociated with other developmental dis-
orders, most notably cardiac malfor-
mations (Olivieri et al., 2002). NKX2-1 
haploinsufficiency has been identified 
in some patients with different degrees 
of  CH together with pulmonary dys-
function, choreoathetosis, and muscu-
lar hypotonia (Krude et al., 2002). The-
re are a few cases in which athyreosis 
is seen in combination with cleft palate 
and spiky hair, with or without bilate-
ral choanal atresia, due to mutations 
in FOXE1 (Castanet & Polak, 2010). 
Also, thyroid dysgenesis is common 
in patients with DiGeorge syndrome, 
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caused by a 22q11 deletion (Stagi et al., 
2009). These patients typically suffer 
from defective development of  the car-
diac outflow tract and PAAs, i.e. closely 
related to the thyroid developmental 
pathway. 
Thanks to neonatal screening pro-
grams, children with CH are generally 
diagnosed early and subjected to hor-
mone substitution therapy, which res-
cues them from severe symptoms such 
as impaired neurological development 
(Seo, Yoon, So, Lee, & Hwang, 2017). 
3.6 THE ORIGIN OF C CELLS
In mammals, C cells become integra-
ted with the thyroid gland instead of  
forming ultimobranchial glands as 
in lower vertebrates. Thyroid C cells 
belong to the neuroendocrine series 
and were originally considered to be 
of  neuroectodermal origin. However, 
the classification of  neuroendocrine 
organs and tissues has changed over 
time according to that more advanced 
techniques have helped to a better un-
derstanding of  the characteristics and 
origins of  different cell types. This 
chapter provides a background to the 
rationale of  investigations in paper I.
3.6.1 The neuroendocrine system 
and the APUD cells
The interactions between neuronal and 
endocrine tissues were recognized early, 
and the understanding of  the regulato-
ry systems of  the human body emerged 
step by step. In 1938, Friedrich Feyrter 
proposed the existence of  a new endo-
crine system with a widespread location 
in many organs, diffusely spread in the 
tissues and with important connections 
to the nervous system (Modlin, Cham-
paneria, Bornschein, & Kidd, 2006). 
He also suggested that these endocri-
ne cells originated from the nervous 
system. The concept of  the neuroen-
docrine system was further supported 
by the works of  others (Pagès, 1957; 
Sunder-Plassmann, 1939) and inclu-
ded thyroid C cells as well as endocrine 
cells from the pituitary gland, adrenal 
glands, stomach, intestine and pancreas 
(Pearse, 1969). 
During the 60s and the 70s the neu-
roendocrine cells were found to have, 
similar to neuronal cells, the capacity 
of  amine precursor uptake and decar-
boxylation, and the acronym APUD 
was suggested as a name of  this group 
of  cells. The APUD cells were thought 
to have a common NC origin (Pearse, 
1969), but it was later shown that most 
of  the cells included in the neuroen-
docrine system were in fact stemming 
from endodermal tissues (Andrew, 
Kramer, & Rawdon, 1982, 1983; Fon-
taine & Le Douarin, 1977; Le Douarin 
& Teillet, 1973). 
Today, the concept of  the neuroendo-
crine system has changed and the mis-
leading APUD acronym is more or less 
abandoned. Rather than focusing on a 
common embryonic origin, the criteria 
for neuroendocrine cells now rely on 
the molecular phenotype, such as the 
production of  neuropeptides and the 
presence of  secretory granules in cells 
that do not signal via synapses (Day & 
Salzet, 2002).
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3.6.2 Tracing neural crest cells using 
quail- chick chimeras
Before genetic tracing techniques were 
available, there were other ways of  
investigating the movement of  cells 
during embryonic development. The 
use of  avian chimeras allowed for the 
tracing of  cells with certain nuclear 
features in a xenograft model (Douarin 
Nicole & Dieterlen‐Lièvre, 2013). This 
studied the fate of  NCCs by surgically 
replacing a defined portion of  the NC 
in chick embryos with the correspon-
ding NC segment obtained from quail 
embryos. The embryos were then left 
to develop and later on examined to 
observe where the quail cells ended up. 
Notably, chick and quail cells can be 
distinguished from each other on the 
basis of  different nuclear characteris-
tics and these experiments showed that 
quail cells migrated to invade a multi-
tude of  embryonic tissues. Quail-chick 
chimeras were thus instrumental in 
characterizing the fate of  NCC which 
revolutionized our understanding of  
vertebrate development (Douarin Ni-
cole & Dieterlen‐Lièvre, 2013). One of  
the conclusions drawn from this model 
was that NCCs populate the ultimo-
branchial gland in the chick embryos. 
The same cells were also found to have 
immunoreactivity for calcitonin, i.e. 
they were identified as C cells (Polak, 
Pearse, Le Lievre, Fontaine, & Le Dou-
arin, 1974). 
3.6.3 Controversies on the embryo-
nic origin of  thyroid C cells
Ever since, the prevailing concept in 
textbooks of  embryology has been 
that C cells are derived from NC also in 
mammals, despite the lack of  evidence 
supporting this idea. As mentioned, in 
all vertebrates except mammals, the UB 
does not fuse with the midline thyroid, 
but forms the ultimobranchial gland. 
Still, the data from experiments in avian 
species on the embryonic development 
of  C cells were extrapolated and assu-
med to hold true also for mammals.
With the development of  better tracing 
techniques and refined imaging possi-
bilities, doubts have been raised regar-
ding the NC origin of  thyroid C cells. 
In 2007, it was shown that tracing of  
cells derived from the NC failed to in-
clude cells that ended up in the mouse 
thyroid, other than stromal cells (Ka-
meda, Nishimaki, Chisaka, Iseki, & Su-
cov, 2007). In paper I, lineage tracing 
of  endoderm progeny was used to in-
vestigate the embryonic origin of  mou-
se C cells.
Thyroid development
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4 Thyroid cancer
”Growth for the sake of  growth is the 
ideology of  the cancer cell”
Edward Abbey
(1927–1989)
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thyroid cAncer
Malignant tumors of  the thyroid re-
present the most common form of  
endocrine cancer and constitute a wide 
spectrum of  phenotypes from tumors 
with excellent prognosis to one of  the 
most aggressive tumors in humans 
(American Cancer Society, 2017; Caba-
nillas, McFadden, & Durante, 2016). 
Most tumors arising belong to the 
group of  differentiated thyroid cancers 
(DTC), all of  which derive from mu-
tant follicular epithelial cells. DTC can 
be further divided into subgroups with 
papillary thyroid carcinoma (PTC), and 
follicular thyroid carcinoma (FTC), 
distinguished by both the histological 
appearance and clinical characteristics. 
These two subtypes are also the most 
prevalent. Poorly differentiated thyroid 
cancers (PDTC) usually exhibit some 
features of  the originating follicular 
cells, but have a more aggressive cour-
se than DTC, due to dedifferentiation 
of  the tumor cells. Anaplastic thyroid 
cancer (ATC) is a completely undiffe-
rentiated and highly malignant tumor. 
It may develop from DTC/PDTC or 
arise de novo, possibly from a stem cell 
population (Cabanillas et al., 2016). 
Medullary thyroid carcinoma (MTC) 
originates from C cells and thus repre-
sents a different entity. MTC tumors 
are neuroendocrine due to their cell 
origin and expression of  calcitonin 
(DeLellis, 2011).
Papers III and IV investigate a mouse 
model for PTC, which warrants a clo-
ser description of  this thyroid cancer 
type in the following. MTC will also be 
briefly described since it forms a back-
ground to part of  the studies in paper 
I. But first a few words on how thyroid 
cancer patients are managed clinically.
4.1 CLINICAL 
PRESENTATION AND 
MANAGEMENT
When a patient presents with thyroid 
enlargement, the possibility of  a thy-
roid cancer has to be considered. Be-
nign thyroid nodules are common and 
among these patients, it is important to 
sort out those where no intervention is 
needed, from those who have a thyroid 
cancer (Haugen et al., 2016). Since the 
thyroid is located close to the trachea, 
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a patient with thyroid enlargement can 
experience symptoms related to com-
pression, such as difficulties in brea-
thing or swallowing. Other symptoms 
may include neck pain, swollen lymph 
nodes, hoarseness or, uncommonly, 
symptoms related to deranged hormo-
ne levels.
In 2016, the American Thyroid As-
sociation (ATA) published updated 
guidelines for the management of  
thyroid nodules and DTC in adult pa-
tients (Haugen et al., 2016). There are 
also guidelines for the management of  
MTC that were published by ATA in 
2015 (Wells et al., 2015). In this section 
the guidelines will be briefly reviewed. 
In Sweden, there is a national program 
for the management of  thyroid cancers 
and this program adheres to the ATA 
guidelines (Regionalt cancercentrum 
väst, 2017). 
If  a thyroid tumor is suspected, a cli-
nical examination and ultrasound-gui-
ded fine-needle aspiration (FNA) for 
cytological evaluation are performed 
and they are the cornerstones of  the 
preoperative, diagnostic procedure. 
Analysis of  serum TSH is performed 
to evaluate the functional state of  the 
thyroid and as prognostic factor, sin-
ce high levels of  TSH indicate a hig-
her risk of  malignancy (Boelaert et al., 
2006; Polyzos et al., 2008). Serum le-
vels of  calcitonin could be determined 
to find indication of  MTC (Elisei et al., 
2004; Wells et al., 2015).
The result of  the cytological exami-
nation is reported according to the 
Bethesda system (Crippa & Mazzuc-
chelli, 2010), which gives an estimation 
of  the risk of  malignant disease. In 
the presence of  malignant cells or su-
spected malignant disease, patients are 
referred to surgical treatement by thy-
roidectomy (see section 4.7 for more 
information on treatment adjuvant to 
surgery). 
4.2 PAPILLARY THYROID 
CARCINOMA (PTC)
4.2.1 Epidemiology and etiology
PTC is the most common form of  thy-
roid cancer and accounts for around 
70 % of  all cases. It occurs three times 
more often in women than in men. 
Thyroid cancers overall has shown a 
markedly rising increase over the last 
decades, mostly due to an increase in 
the incidence of  PTC (Kilfoy et al., 
2009; La Vecchia et al., 2015). Reasons 
for this have been a matter of  debate. 
Even if  improved diagnostic tools is li-
kely to explain most of  it, there is still 
an increased number of  cancer patients 
also diagnosed with large tumors that 
cannot be explained by known factors 
(Kitahara & Sosa, 2016). 
One important environmental factor 
that leads to higher risk of  PTC is the 
exposure of  ionizing radiation, due to 
both medical x-ray examinations and 
incidental ingestion of  radioactive io-
dine after nuclear plant accidents. The 
Chernobyl catastrophe is an example 
of  how exposure of  radioactive isoto-
pes being spread all over Eastern Eu-
rope, in particular Ukraine and Belarus, 
caused an alarming increase in the in-
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cidence of  childhood PTC (LiVolsi et 
al., 2011; Williams, 2006). Other less 
well characterized risk factors of  de-
veloping thyroid cancer include repro-
ductive factors (Rahbari, Zhang, & Ke-
bebew, 2010), dietary factors (Z.-T. Liu 
& Lin, 2014), smoking (Cho & Kim, 
2014) and diabetes (Yeo et al., 2014). 
4.2.2 Histology and subtypes of  
PTC
The microscopic diagnosis of  PTC is 
based on the presence of  a papillary 
growth pattern and typical nuclear fea-
tures, including change of  nuclear size, 
pseudoinclusions, nuclear grooves, and 
ground glass nuclei in the tumor cells 
(Albores‐Saavedra, Altamirano‐Dimas, 
Alcorta‐Anguizola, & Smith, 1971; 
Lloyd, Osamura, Klöppel, & Rosai, 
2017). The last phenomenon has also 
been described as clear nuclei or orp-
han Annie nuclei (Dominguez‐Malag-
on Hugo, Szymanski‐Gomez Juan, 
& Gaytan‐Garcia Silvia, 2006). The 
predominant growth pattern is cha-
racteristic with papillary formations 
that can form straight or branching 
cords. Sometimes there are also other 
growth patterns in combination, such 
as follicular or trabecular arrangements 
(Lloyd et al., 2017). 
Apart from the classical PTC there are 
14 variants listed by WHO and their na-
mes refer to typical features in each of  
them regarding size (microcarcinoma), 
tumor cell shape (tall cell, columnar 
cell, hobnail, oncocytic, spindle cell and 
clear cell variants), secondary growth 
pattern (follicular, diffuse-sclerosing, 
cribriform-morular, and solid/trabecu-
lar variant) or the stromal contribution 
(encapsulated, PTC with fibromatosis/
fasciitis-like stroma, Warthin-like vari-
ants) (Lloyd et al., 2017).
PTC subtyping is of  prognostic value. 
However, due to lack of  suitable mo-
dels for experimental investigation, the 
basic mechanisms behind the differen-
ces in tumor cell behavior of  PTC sub-
types, conferring accelerated growth, 
local invasiveness and metastasizing 
capacity, are largely unknown. Paper 
III presents a novel PTC mouse mo-
del that might be instrumental on these 
aspects.
4.3 MEDULLARY THYROID 
CARCINOMA (MTC)
4.3.1 Epidemiology and etiology
MTC derives from C cells and accounts 
for around 5-10 % of  all thyroid can-
cers. Most cases are sporadic, but app-
roximately 25 % of  cases are heredita-
ry, either as familial MTC (FMTC) in 
isolation, or as a part of  the multiple 
endocrine neoplasia (MEN) syndrome 
type 2A or 2B (Leboulleux, Baudin, 
Travagli, & Schlumberger, 2004). In 
MEN 2A, MTC is associated with pha-
eocromocytoma and hyperparathyroi-
dism, while in MEN 2B, MTC occurs 
together with phaeochromocytoma, 
ganglioneuromatosis and different 
muscular and skeletal malformations.
MTC is mostly located at the junction 
between the two upper thirds of  the 
gland. In 20 % of  cases, distant metast-
ases are present already at diagnosis, 
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most often in the liver, lungs or bones 
(Leboulleux, Baudin, Travagli, & Sch-
lumberger, 2004). 
4.4 THE MAPK/ERK 
SIGNALING PATHWAY
Several oncogenic mutations are in-
volved in the development of  thyroid 
cancer. They mostly affect the mito-
gen-activated protein kinase (MAPK) 
pathway, which motivates a closer pre-
sentation of  its key signaling molecu-
les. Within this pathway there are se-
veral cascades with different mediators 
(Pritchard & Hayward, 2013). This des-
cription will focus on the cascade that 
ends with the extracellular signal-regu-
lated kinase (ERK) and this pathway is 
also called the MAPK/ERK pathway. 
These are the players in the pathway:
• RTK
• Ras
• Raf
• MEK
• ERK
Fig 14. Schematic illustration of  the MAPK/ERK pathway. A receptor tyrosine kinase (RTK) is shown, located 
at the basal plasma membrane of  a follicular cell. When a ligand binds, the RTK will activate Ras, which in turn 
activates Raf  - MEK - ERK - various targets. Mutant Braf  is constitutively active and can activate downstream 
targets even in absence of  Ras signaling. 
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4.4.1 Receptor tyrosine kinase
Receptor tyrosine kinases (RTKs) are 
membrane-spanning proteins located 
at the cell surface. Commonly they 
form dimers after binding of  their li-
gand which causes autophosphory-
lation required for activation of  the 
receptor (McKay & Morrison, 2007). 
The activated receptor can then elicit 
different cascades of  intracellular sig-
naling to control cell activity such as 
cell differentiation, proliferation and 
migration (Schlessinger, 2000). I will 
here focus only on elements that even-
tually activates ERK.
4.4.2 Ras
After RTK, the next step in the MAPK 
pathway is the small G protein Ras, 
which can exist in a guanosine diphosp-
hate(GDP)-bound, inactive or a guan-
osine triphosphate(GTP)-bound, acti-
ve state (Bar-Sagi & Hall, 2000). RTK 
activation stimulates the exchange of  
GDP for GTP by guanine nucleotide 
exchange factors (GEFs) to activate 
Ras. The GTP of  the activated Ras will 
then be hydrolysed to GDP by GTPa-
se activating proteins (GAPs) and the 
protein will return to its inactive state 
(Lowy & Willumsen, 1993). 
There are three Ras genes (H-ras, N-ras, 
and K-ras) encoding four proteins that 
play slightly different roles in cellular 
signaling. The different isoforms can 
undergo oncogenic activation and they 
were discovered due to their involve-
ment in different cancers. Oncogenic 
activation is related to mutations that 
keep the protein in an active state, thus 
the pathway is constitutively activated, 
causing aberrant signaling (Castellano 
& Santos, 2011).
4.4.2 Raf  
The Raf  family includes three serine/
threonine kinases and follows Ras ac-
tivation in the MAPK pathway. The 
Raf gene was first discovered through 
the cloning of  a viral oncogenic that 
induces rapidly growing fibrosarcoma 
in mice and this oncogene was called 
v-raf, which later was found to have a 
homologue, c-raf, in eukaryotic cells 
(Rapp et al., 1983; Schreck & Rapp, 
2006). Additional homologues were 
found in mammals and named a-raf and 
b-raf (Daum, Eisenmann-Tappe, Fries, 
Troppmair, & Rapp, 1994). 
All the three Raf  kinases possess th-
ree conserved regions, CR1, CR2, and 
CR3 that are important for their func-
tion and regulation. CR1 is a domain to 
which Ras binds and activates Raf. CR2 
can bind an inhibitory protein to nega-
tively regulate the kinase activity. Lastly, 
CR3 is the protein kinase domain that 
phosphorylates the downstream kinase 
MEK (Lavoie & Therrien, 2015; Ze-
bisch & Troppmair, 2006).
4.4.3 MEK and ERK
There is substantial cross talk 
between different intracellular sig-
naling pathways, but the only known 
downstream target for the Raf  kinases 
is MEK (MAPK/ERK kinase) which in 
turn only have one downstream target 
in ERK (extracellular regulated kinase). 
Activation of  ERK by MEK facilitates 
its transport into the nucleus where it 
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regulates transcription factors involved 
in processes such as cell proliferation 
and differentiation (Plotnikov, Zehorai, 
Procaccia, & Seger, 2011; Yang, Shar-
rocks, & Whitmarsh, 2013). 
To summarize, the MAPK pathway 
receives extracellular signals activating 
an intracellular signaling cascade that 
alters transcription of  target genes. 
Modification and regulation of  the sig-
nal is possible at several levels. Because 
of  the crosstalk between the MAPK 
and other signaling pathways, there are 
many outcomes possible through a li-
mited number of  kinases involved. 
4.5 MUTATIONS OF THE 
MAPK PATHWAY
Genetic alterations conferring consti-
tutive activation of  the MAPK pathway 
are common oncogenic drivers in va-
rious cancers. The most prevalent mu-
tations leading to cancer development 
involves RAS and RAF, leading to un-
controlled tumor cell proliferation and 
often also dedifferentiation (Karnoub 
& Weinberg, 2008; Pylayeva-Gupta, 
Grabocka, & Bar-Sagi, 2011). Interes-
tingly, mutations of  Ras and Raf  are 
mutually exclusively and are never en-
countered in the same tumor cell (Ci-
sowski, Sayin, Liu, Karlsson, & Bergö, 
2015; Rajagopalan et al., 2002).
4.5.1 Braf  mutations
Mutated BRAF occurs in 40-45 % of  
PTC cases (R. Ciampi & Nikiforov, 
2005; Cohen et al., 2003; E. T. Kimura 
et al., 2003). Besides being involved in 
thyroid cancer, mutant BRAF is often 
found in melanomas and colorectal 
cancer (Rajagopalan et al., 2002). Most 
of  the known oncogenic BRAF muta-
tions involve alterations at or close to 
the sequence that encodes for the acti-
vation site of  the kinase (Davies et al., 
2002). The most prevalent mutation is 
a substitution of  glutamic acid for vali-
ne at position 600 (BrafV600E), by which 
the encoded kinase constantly posses-
ses its activated conformation (Ikenoue 
et al., 2004). 
The effects on cell behavior as a re-
sponse to Raf  signaling differs due to 
different levels of  kinase activity. This 
means that a higher level of  kinase acti-
vity does not necessarily lead to increa-
sed cell proliferation. Instead, increased 
Raf  activity due to mutation/overex-
pression has in some cases been shown 
to induce cell cycle arrest (Woods et al., 
1997). This highlights the complex na-
ture of  the MAPK signaling pathways 
regulating cell growth responses.
In mouse thyroid, conditional expres-
sion of  BrafV600E initiates tumorigenesis 
and also dedifferentiation of  neoplas-
tic thyroid cells (Knauf  et al., 2005). It 
downregulates the genes for NIS, Tg 
and TPO, and therefore impairs nor-
mal thyroid function severely. A similar 
model of  thyroid cancer development 
forms the basis of  the studies in papers 
III and IV.
4.5.2 RAS mutations
Mutations of  all three isoforms HRAS, 
KRAS and NRAS, are all found in thy-
roid cancers (Howell Gina, Hodak Ste-
ven, & Yip, 2013; Suarez et al., 1990). 
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RAS mutations are most prevalent in 
FTC and are also reported to occur 
in the follicular variant of  PTC (Zhu, 
Gandhi, Nikiforova, Fischer, & Niki-
forov, 2003). This indicates that mutant 
Ras acting upstream of  Braf  confers a 
different tumor phenotype, which is in-
teresting. Besides activating the MAPK 
pathway, participation of  Ras signaling 
in other pathways, most notably PI3K/
AKT, may explain the differential on-
cogenic response (Z. Liu et al., 2008). 
4.5.3 RET mutations
RET is a proto-oncogene that was 
found in 1985 and the name comes 
from Rearranged upon Transfection 
(Takahashi, Ritz, & Cooper, 1985). 
RET encodes an RTK and is involved 
in the MAPK pathway but, like RAS, it 
also effects the PI3K pathway (Besset, 
Scott, & Ibáñez, 2000; Hayashi et al., 
2000). There are two types of  genetic 
alterations that make RET oncogenic. 
First, there are point mutations that 
occur both as sporadic mutations and 
germ line mutations. This type of  alte-
ration is typically found in MTC and the 
MEN2 syndrome. Second, the tyrosine 
kinase domain may fuse with another 
gene, so-called RET/PTC rearrang-
ements, that encodes an intracellular 
oncogenic fusion protein. RET/PTC is 
found in 20-40 % of  PTC cases (Raffa-
ele Ciampi & Nikiforov, 2007; Romei, 
Ciampi, & Elisei, 2016).
4.6 ONCOGENE-INDUCED 
SENESCENCE AND 
THE ROLE OF TSH
Cell cycle arrest in response to oncoge-
ne activity is called oncogene-induced 
senescence (OIS) and has entered the 
limelight in recent years. Similar to cel-
lular senescence well-known as a limit 
for the propagation of  cells in cell cul-
ture, OIS leads to cell cycle arrest in the 
G1 phase, accompanied by slowdown 
of  cellular metabolism and also morp-
hological changes (Reddy & Li, 2011). 
Cells that are senescent typically beco-
me flat and elongated. They also ex-
press tumor suppressor proteins such 
as p16 and p53, which are important 
in mediating cell cycle arrest (Moulana, 
Priyani, de Silva, & Dassanayake, 2018). 
Conceivably, OIS prevents cells from 
propagating DNA damage to their 
progeny, and is therefore important in 
protecting the organism from cells that 
might malignify and give rise to cancer. 
However, OIS can be overcome by dif-
ferent mechanisms. In the thyroid, in-
creased TSH signaling can overcome 
OIS and lead to tumor development 
(Zou et al., 2015). In a hypothyroid sta-
te, the pituitary gland compensates by 
increased levels of  TSH. Such a state 
sometimes occurrs in thyroid tumors, 
since mutant Braf  causes dedifferenti-
ation and loss of  functioning epitheli-
um. Also, mutant Braf  upregulates the 
TSH receptor on the follicular cells and 
amplifies the effect of  TSH signaling in 
thyroid cells (Moulana et al., 2018).
4.7 TARGETED TREATMENT 
STRATEGIES
The standard treatment for PTC is sur-
gery, often combined with radioactive 
iodine (RAI) therapy and occasionally 
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external beam therapy (Haugen et al., 
2016). The principle behind RAI is that 
follicular cells are the only cells in the 
body with a possibility to concentrate 
iodine. When a patient receives treat-
ment with RAI, the effect is therefore 
restricted to the thyroid (or metastases 
from thyroid cancer), sparing other tis-
sues. RAI has been used for the treat-
ment of  hyperthyroidism and thyroid 
cancer since the early 40s (Daniels, 
2012; Gold, 1951). The isotope used in 
clinical practice is 131I and one prerequi-
site for successful RAI therapy is that 
the tumor cells express NIS, so that 
radioiodine can be concentrated intra-
cellularly or accumulated in preserved 
follicular lumens to achieve a sufficient 
radiation dose and therapeutic effect. 
An obvious problem is dedifferentia-
tion, prevalent in many PTC tumors, 
in which mutant Braf  down-regulates 
the expression of  NIS, making tu-
mor cells refractory to RAI treatment 
(Schlumberger, Lacroix, Russo, Filetti, 
& Bidart, 2007). 
Advances in the understanding of  on-
cogenic drivers in cancer have led to 
the development of  drugs that speci-
fically inhibits various kinases invol-
ved in the MAPK and other signaling 
pathways. Several tyrosine kinase in-
hibitors (TKIs), as vandetanib, cabo-
zantinib, sorafenib, and lenvatinib have 
been approved for adjuvant treatment 
of  advanced thyroid cancer (Valerio et 
al., 2017). This type of  treatment holds 
promise in that it affects the pathways 
that are directly involved in tumor de-
velopment. However, they also have 
severe side effects that limit their use 
and only patients with advanced cancer 
are subjected to this kind of  therapy 
(Mohammed & El-Shentenawy, 2014). 
Drug resistance is also a limiting factor.
Vemurafenib (PLX4032) is a TKI that 
is active against mutant Braf  (Joseph et 
al., 2010). It has been approved for the 
use in patients with melanoma (Kim et 
al., 2014) and effects the dimerization 
of  BRAF, impairing its activity (Karou-
lia, Gavathiotis, & Poulikakos, 2017). 
In paper IV, vemurafenib was tested 
for inhibition of  early tumorigenesis in 
the BrafV600E mouse model of  PTC.
The outcome for thyroid cancer pa-
tients with adequate treatment is very 
good, and the 10-year relative survival 
is more than 90 % for all histologi-
cal types. PTC has the best prognosis 
with a 10-year relative survival of  98 
%, while the corresponding numbers 
for FTC is 92 %, for MTC 80 %, and 
for anaplastic cancer 13 % (Gilliland, 
Hunt, Morris, & Key, 1997).  
4.8 CANCER 
DEVELOPMENT
Tumors elicited by one and the same 
oncogenic mutation show a phenotypic 
heterogeneity that reflects the com-
plexity not only of  the genetic events 
that lead to cancer, but also of  the ori-
ginating cells that are primarily muta-
ted (Visvader, 2011). The development 
of  cancer is often described as a chain 
of  events that leads to transformation 
of  a normal cell. Such a cell is called a 
tumor-initiating cell (TIC) and should 
be distinguished from cancer stem cells 
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(CSCs), which function as tumor-pro-
pagating cells. TIC and CSC are some-
times used synonymously, which may 
be confusing (Rycaj & Tang, 2015; Vis-
vader, 2011). The concept of  CSCs is 
still evolving and their origin and cha-
racteristics are uncertain (Hanahan & 
Weinberg, 2011). However, the nature 
of  TICs is of  fundamental interest to 
understanding tumor heterogeneity. 
For example the differentiation status 
of  a TIC might influence its progress 
in tumor development and explain dif-
ferences in tumor phenotypes arising 
from identical oncogenic mutations. In 
skin cancer, there are studies that argue 
for a stem cell origin, as well as for an 
origin in mature cells that dedifferen-
tiate and initiate tumor development 
(Köhler et al., 2017; Malanchi et al., 
2008). 
As previously mentioned the BrafV600E 
mutation is involved in tumor-initiation 
in several tissues, such as the colon and 
the skin. These tumors do not progress 
to malignant disease unless other ge-
netic alterations appear. In contrast, 
BrafV600E has shown the ability to alo-
ne transform follicular cells and cause 
them to progress to PTC (Knauf  et al., 
2005). This implies different suscepti-
bility of  the tumor-initiating cells 
between different organs and tissues. 
The mechanism behind this difference 
is poorly understood but may be related 
to the inborn growth regulation that 
differs much among cell types. In both 
colon and skin, there is a high turnover 
of  the epithelial cells and homeostasis 
is achieved through the presence of  tis-
sue stem cells that constantly renew the 
epithelium to compensate for the con-
tinuous loss of  cells through shedding 
at the epithelial surface (Yan & Ow-
ens, 2008). This is in sharp contrast to 
thyroid follicular cells, which normally 
replicates around five times during the 
normal human life-span (Coclet et al., 
2008). A high turnover means that cells 
have less time to accumulate additional 
mutations, which means that cells in 
for example the skin and intestine are 
protected by their short lifespan.  
Another level of  tumor heterogeneity 
concerns the phenotypic variations of  
PTC, which range from microcarcino-
ma to advanced and invasive tumors, 
with different prognostic outcome. 
Notably, among the majority of  PTC 
cases that carry the BrafV600E mutation, 
the whole spectrum of  tumor phenoty-
pes exist of  which only a minority pro-
gresses to advanced disease with mor-
tality risk. Present conditional mouse 
PTC models, in which mutant Braf  is 
globally and synchronously expressed 
in all thyroid cells are invalid for in-
vestigation of  a possible heterogenic 
response of  single tumor cells within 
the normal thyroid microenvironment.
In papers III and IV, a new mouse 
model of  sporadic PTC was develo-
ped and characterized on the basis of  
spontaneous Cre-induced BrafV600E ac-
tivation. This model allowed for the 
detailed study of  tumor initiation and 
development.
5 Aims of  the thesis
”Never be so focused on what you are 
looking for that you over look the thing 
you actually f ind”
Ann Patchett 
(b. 1963)
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Aims of the thesis
The aims of  the thesis were to investigate: 
• a possible endodermal embryonic origin of  thyroid C cells and its implica-
tions for the tumor phenotype in medullary thyroid carcinoma
• epithelial and migrating properties of  embryonic C cells before, during and 
after fusion of  the ultimobranchial bodies with the embryonic thyroid
• BrafV600E-induced tumor development in the natural microenvironment by ge-
nerating a mouse model of  sporadic papillary thyroid cancer (PTC)
• tumor initiation and clonal development of  thyroid microcarcinomas from 
single Braf  mutant follicular cells
• effect of  a Braf  V600E inhibitor on early tumorigenesis in the sporadic PTC 
model
6 Methodology
”A scientist  in his laborator y is not a mere 
technician: he is also a child confronting 
natural phenomena that impress him as 
though they were fair y tales”
Marie Curie
(1867–1934)
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methodoLogy
Different techniques to intervene with, 
trace, and image cells form the cor-
nerstone of  this thesis. Each of  them 
presents with different advantages and 
disadvantages. In this chapter, the most 
important techniques used in the four 
papers will be explained and discussed. 
6.1 GENETIC ENGINEERING
Creating genetic alterations in cell cul-
ture or laboratory animals is a way to 
achieve important information about 
the functions of  specific genes (Bouabe 
& Okkenhaug, 2013). To knockout 
a gene and then simply observe what 
happens is an appealing strategy, but 
it has turned out that it is not an as 
straightforward approach as one could 
wish. A single genes is involved in so 
many functions in an organism. The-
refore, deleting one gene often causes 
such profound effects that it is difficult 
and sometimes impossible to discern 
its functions in a given tissue context. 
Also, some genes are crucial during 
embryonic development and their ab-
sence could therefore be embryonically 
lethal, precluding the study of  the func-
tion later on in development or in adult 
animals (Doyle, McGarry, Lee, & Lee, 
2012). Yet another complicating factor 
is that many genes cooperate with 
other genes so that the effect of  a sing-
le gene knockout may be related to al-
tered functions of  partner gene(s). So-
metimes there is redundancy between 
two or more genes, so that deletion of  
either one of  the genes causes little or 
no effect; knockout of  both is required 
to uncover a dysregulated mechanism.
6.1.1 Cre/loxP-system
The discovery of  the bacterial re-
combinase Cre (the name is short for 
causes recombination) has provided 
important new tools for genetical engi-
neering. Cre is an enzyme that recogni-
zes specific nucleotide sequences called 
loxP (from locus of  x-over of  bacte-
riophage P1) sites (Sternberg & Ham-
ilton, 1981). The loxP site is a DNA 
sequence of  34 basepairs with a centre 
of  8 basepairs and two palindromic 13 
basepair sequences on each side of  the 
centre. This sequence does not occur in 
the natural mouse genome, but it can 
be inserted on each side of  a specific 
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gene and this gene is then said to be 
floxed (flanked by loxP). Cre is able to 
cause recombination between two loxP 
sites and the result can be deletion or 
inversion of  the gene depending on the 
direction of  the loxP sites (Smedley, 
Salimova, & Rosenthal, 2011). See Fi-
gure 15 for a schematic representation 
of  the Cre/loxP system.  
6.1.2 Spatial control of  Cre 
expression
The application of  the Cre/loxP-sys-
tem in transgenic mice has opened new 
possibilities in tailoring mouse models 
of  disease or for the understanding of  
normal gene function in a given or-
gan, tissue or cell type (Orban, Chui, & 
Marth, 1992). Typically a tissue-specific 
promoter controls the expression of  
Cre. Thus, the expression of  Cre can 
be restricted, allowing for spatial con-
trol of  the genetic event caused by Cre 
to only the cells that normally express a 
gene controlled by the same promoter. 
Other cells will not express Cre and a 
floxed gene in these cells remains unaf-
fected. To date, there is a plethora of  
different Cre drivers, which enables 
studies of  numerous variants designed 
for conditional manipulation of  the 
targeted genes of  interest (Nagy, Mar, 
& Watts, 2009). 
6.1.3 Temporal control of  Cre 
expression
Many genes are crucial for embryonic 
development and their early deletion 
could make it impossible to investiga-
te their role in adulthood. To achieve 
temporal control of  Cre-mediated re-
combination, some variants have been 
designed in which Cre is coupled to 
an additional element that restricts it 
to the cytoplasm. Cre-ERT2 is a variant 
in which a modified estrogen receptor 
is coupled to Cre and prevents it from 
entering the cell nucleus to perform re-
combination (Feil, Wagner, Metzger, & 
Chambon, 1997). Upon binding to the 
receptor by its ligand tamoxifen, Cre 
will be allowed to enter the nucleus. 
Thanks to this, the effect of  Cre-de-
pendent recombination can be tem-
porally controlled and prevented until 
administration of  the inducing agent. 
6.1.4 Knock-outs and knock-ins
The Cre/loxP-system is a very con-
venient tool since it only requires two 
principal elements to create a genetic 
alteration. The system can produce 
both conditional deletion (knockout) 
and conditional expression (knockin) 
of  specific genes, see example in figure 
16. To accomplish this, a gene is flox-
ed, or a floxed stop-cassette is placed 
upstream of  a gene (that might be en-
dogenous or inserted), respectively. A 
floxed stop-cassette prevents the ex-
pression of  the gene. Cre-mediated re-
combination then removes the floxed 
gene (knock-out) or the stop-cassette 
(knock-in). In the latter case removal 
of  the stop-cassette makes the gene av-
ailable for transcription. This allows for 
the study of  loss- or gain-of-function 
of  the gene after recombination (Doyle 
et al., 2012). 
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6.1.5 Problems in using Cre/loxP
Several unexpected findings have 
shown that there are important aspects 
to consider when using the Cre/
loxP-system and interpreting results 
obtained from it. For example, animals 
expressing Cre might have an altered 
phenotype even in the absence of  re-
combination (Forni et al., 2006; Loons-
tra et al., 2001). Another issue concerns 
the fidelity of  spatial and temporal con-
trol elements. Unexpected Cre expres-
sion in off-target tissues has been re-
ported and leads to a more widespread 
Fig 15. The Cre/loxP-system. A transgenic mouse with a tissue-specific Cre driver is bred with another transgenic 
mouse with  a floxed target gene (upper two mice). In offspring (lower mouse) that has inherited both alleles, the Cre 
driver will perform recombination between the two loxP sites, thus deleting the target gene. 
loxP loxP
loxP loxP
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Cre-mediated recombination than de-
sired (Heffner et al., 2012). This could 
be referred to as promoter leakiness. 
Another type of  leaky or spontaneous 
activity is the activity of  inducible Cre 
in absence of  the inducing agent. In 
fact, this may also be advantageous as 
will be apparent discussing the results 
presented in Papers III and IV.
Even in cases of  successful recombi-
nation in the desired tissue, the effect 
might not be the expected. There are 
findings of  persistent protein expres-
sion following confirmed excision of  
a gene, due to episomal retention of  
the excised gene (Turlo, Gallaher, Vora, 
Laski, & Iruela-Arispe, 2010). 
Nonetheless, the Cre/loxP-system is 
considered to be a robust system with 
high fidelity, but carefulness is still war-
ranted when using this method.
6.2 LINEAGE TRACING 
AND REPORTERS
To study the dynamics of  embryonic 
processes it is important to be able to 
trace cells in relation to some previo-
us stages of  development. In Paper I, 
the tracing of  cells from different germ 
layers was an important matter. This 
was achieved by combining Cre drivers 
with reporter genes previously known 
to be germ layer-specific. Sox17-2A-Cre 
was used as a driver to express Cre in 
endoderm cells, in which the transcrip-
tion factor Sox17 is ubiquitously ex-
pressed before organogenesis from the 
foregut (Engert et al., 2009). This was 
coupled to a reporter mouse strain that 
expressed β-galactosidase upon Cre-ac-
tivation (Soriano, 1999). The design of  
the reporter gene is such that it conta-
ins a floxed stop codon, preventing its 
expression. Upon Cre recombination, 
β-galactosidase is expressed under the 
control of  a ubiquitous promoter, en-
suring stable expression as soon as the 
stop codon is removed. Tissues that are 
β-galactosidase positive, can be iden-
tified by their ability to use x-gal as a 
substrate to produce blue color, easi-
ly recognized in the light microscope. 
The advantage in this setup is that all 
progeny of  a cell previously expressing 
Sox17, will express β-galactosidase. In 
our case, this provides a means to tra-
ce all cells that were once a part of  the 
endoderm, regardless of  their develop-
mental fate. 
Another reporter that was used in Pa-
pers I and IV is the double-fluorescent 
reporter mTmG, in which all cells ex-
press the red fluorescent protein To-
mato before recombination. When Cre 
is active, it will excise the Tomato gene 
(mT) including a following stop-cas-
sette, thus allowing for the expression 
of  the green fluorescent protein GFP 
(mG) instead (Muzumdar, Tasic, Mi-
yamichi, Li, & Luo, 2007). In both 
constructs, the encoded fluorescent 
proteins are membrane-bound (deno-
ted by m in mTmG), providing sharp 
contours of  the plasma membrane. 
This allows evaluation of  cell shape 
changes in cells that co-express e.g. 
mutant Braf.
Methodology
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6.3 TRANSGENIC 
MOUSE MODELS OF 
THYROID CANCER
Mouse models are commonly used in 
the study of  human cancers. One im-
portant approach is to use patient-de-
rived xenograft (Pdx) models, in which 
tumor specimens from patients are 
implanted to immunodeficient mice, 
either subcutaneously or orthotopically 
(Einarsdottir et al., 2014). This allows 
for the study of  human cancer cells in 
vivo and also to test targeted treatments 
with e.g. kinase inhibitors that may pro-
vide valuable information on the ex-
pected therapeutic response in patients. 
In a xenograft model of  PTC, a human 
cancer cell line with Braf-mutant PTC 
showed tumorigensis in transplanted 
nude mice (D. Liu, Liu, Condouris, & 
Xing, 2007). One disadvantage with 
this approach is that the immune sys-
tem of  the host mouse needs to be 
suppressed, which makes it less faithful 
in mimicking the human cancer micro-
environment. 
Already in 1996, a mouse model of  
PTC was established, in which the 
RET/PTC fusion protein was expres-
sed in follicular cells under control of  
the Tg promoter (Santoro et al., 1996). 
In this model, mice developed PTC 
slowly, but with a normal life-span. 
Employing the Cre/loxP-system to ge-
nerate genetically modified mice with 
activated oncogenes or inactivated tu-
mor suppressor genes has generated 
novel information on mechanisms of  
endogenous tumor development and 
progression. One of  the first mouse 
models of  BrafV600E-induced oncogenic 
transformation of  cells was reported 
for thyroid (Knauf  et al., 2005) and 
lung (Dankort et al., 2007), leading to 
PTC and lung cancer, respectively. In 
most instances, BrafV600E-induced PTC 
used a strategy to constitutively express 
the floxed transgene from the onset 
of  expression of  the Cre-driving gene, 
mostly Tg, which implies that cells are 
transformed already in embryonic de-
velopment (Charles, Iezza, Amendola, 
Dankort, & McMahon, 2011; Franco 
et al., 2011; Knauf  et al., 2005; Orim 
et al., 2014). In Papers III and IV, a 
tamoxifen-inducible Cre driver, con-
trolled by the thyroglobulin promoter 
(Undeutsch, Lof, Offermanns, & Kero, 
2014), was combined with a floxed 
BrafV600E transgene to generate a more 
representative model of  PTC develop-
ment in adult mice. 
7 Summar y of  results
”We ourselves feel  that what we are 
doing is just a drop in the ocean. But 
the ocean would be less because of  that 
missing drop”
Mother Teresa
(1910–1997)
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summAry of resuLts
7.1 PAPER I
Revising the embryonic origin 
of  thyroid C cells in mice and 
humans
In paper I, the origin of  mouse thyroid 
C cells was investigated. Experiments 
on chick-quail-chimeras in the 70s led 
to the conclusion that C cells in avian 
species are derived from neural crest 
cells (Polak et al., 1974). It was then 
believed that this was the case also in 
mammals. However, the conclusions 
from these experiments have been 
challenged by other studies indicating 
an endodermal origin of  C cells in 
mice and warranting the closer study 
of  their origin in mammals (Adams & 
Bronner-Fraser, 2009; Kameda et al., 
2007). 
Lineage tracing of  cells derived from 
the neural crest was conducted, using 
the Cre/loxP-system in which Cre de-
pendent activation of  the double-flu-
orescent reporter mTmG was mediated 
by Wnt1, known to be expressed in ear-
ly development only in the neural crest. 
Cells with a history of  Wnt1 expression 
could thus be traced by their color con-
version from red to green fluorescent 
protein (Tomato/GFP) and cells that 
had never expressed Wnt1 remained 
red. Neither follicular cells nor C cells 
were found in the GFP+ cell popula-
tion. This ruled out the possibility of  
a C cell origin from Wnt1+ neural crest 
progeny. Next, the possibility of  an 
origin in embryonic endoderm was te-
sted through similar tracing of  the fate 
of  cells from Sox17+ endoderm. This 
showed that C cells, identified by their 
expression of  calcitonin, belonged to 
the progeny of  Sox17+ endoderm. The 
co-localization of  Sox17-dependent 
expression of  β-galactosidase and cal-
citonin was confirmed by laser con-
focal microscopy to ensure that the 
identifying signals were indeed obtai-
ned from the same cell. Thus, mouse 
thyroid C cells are endodermal.
Next, the expression of  the endoder-
mal markers Foxa1 and Foxa2 was in-
vestigated during development of  the 
thyroid in mouse embryos and also in 
human MTC. Both were gradually in-
duced in the developing ultimobran-
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chial epithelium, whereas the thyroid 
primordium did not express Foxa1/2 
at any developmental stage. This sug-
gested the Foxa genes are functionally 
important for development of  C cell 
precursors, correlating with their pro-
liferation pattern. In tumor specimens, 
we found that Foxa1 had a growth-pro-
moting role, and that tumor cells with 
invasive properties showed a coordi-
nated loss of  Foxa2 expression and 
E-cadherin that were re-expressed in 
metastases. This suggested that Foxa1 
and Foxa2 may participate in MTC tu-
mor progression and that MTC tumor 
cells undergo transient EMT. 
7.2 PAPER II
Guidance of  parafollicular 
cells (C cells) to the embryonic 
thyroid involves remodeling of  
basement membrane
It is presently unknown how thyroid C 
cells achieve their parafollicular posi-
tion in the thyroid gland. Paper II gives 
a detailed description of  the morpho-
genetic changes that the UB epithelium 
undergoes foregoing the entry of  UB 
cell precursors into the embryonic thy-
roid. It also correlates functionally this 
process to basement membrane (BM) 
degradation. 
Wild-type mouse embryos were stu-
died from the budding of  thyroid pri-
mordia in the pharyngeal endoderm to 
the onset of  folliculogenesis in the pri-
mitive thyroid lobes (ages E9.5-15.5). 
In addition, Pax8 null and Nkx2-1 he-
terozygous mutants with altered UB 
development, to various degree inde-
pendent of  the midline thyroid, were 
investigated at E15.5. Both the midline 
thyroid (MT) and the UBs were found 
to be enveloped by a continuous BM 
during budding and early migration. 
However, prior to fusion, laminin stai-
ning and ultrastructural analysis showed 
that the BM of  the UBs was gradually 
degraded. Localization of  polarity mar-
kers (pericentrin and giantin) indicated 
loss of  apical polarity and multilayering 
of  the UB epithelium, albeit with pre-
served expression E-cadherin and thus 
the epithelial phenotype. 
Laminin degradation on the UB surfa-
ce occurred in a cell-autonomous way 
and required both Nkx2-1-alleles to be 
accomplished. This process facilitated 
UB-thyroid fusion and formation of  a 
composite gland. Together, these fin-
dings provide a mechanism by which 
thyroid follicular cells and C cells meet 
and end up in such an intimate con-
tact in the mature gland. Is also expla-
ins how embryonic C cells acquire a 
pro-migratory phenotype.
7.3 PAPER III
Follicular origin of  tumor he-
terogeneity in a mouse model 
of  sporadic papillary thyroid 
cancer
Existing mouse models of  thyroid can-
cer commonly use genetic engineering 
to conditionally activate oncogenes or 
inactivate tumor suppressor genes of  
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known importance in humans (Kirsch-
ner, Qamri, Kari, & Ashtekar, 2016). 
This enables global expression in the 
entire gland, leading to rapid tumor 
development, which gives opportuni-
ties to study factors that modify tumor 
growth and progression. However, 
since most if  not all thyrocytes are 
simultaneously transformed, present 
transgenic models lacking a natural mi-
croenvironment are far from mimick-
ing the development of  human thyroid 
cancer. 
In paper III, we used an inducible mou-
se model of  papillary thyroid cancer 
PTC, in which a BrafV600E mutation was 
conditionally activated only in thyroid 
follicular cells expressing Cre under 
control of  the Tg promoter. Induction 
with tamoxifen generated tumorous 
growth encompassing the entire gland. 
However, we discovered spontaneous 
Cre activation in the absence of  ta-
moxifen and that microtumors deve-
loped multifocally, originating in single 
follicles, with closely located normal 
follicular tissue. Eventually, large tu-
mors with signs of  local invasion deve-
loped. Interestingly, tumor foci present 
in the same gland showed different 
phenotypes (classical, tall-cell, hobnail, 
cystic and solid variants) recognized in 
PTC in humans. Contrary to after ta-
moxifen-induced tumorigenesis, the 
sporadic tumors developed with nor-
mal thyroid hormone and TSH levels. 
Braf  mutant tumor cells with hobnail 
appearance showed signs of  oncoge-
ne-induced stress response (dilated 
endoplasmic reticulum and autopha-
gosomes). Thus, this model enabled 
the detailed study of  different stages in 
tumor development under conditions 
that closely resemble tumor develop-
ment in humans.
7.4 PAPER IV
Tracing tumor-initiating cells 
in BrafV600E-induced thyroid 
cancer
Although it has not been formally pro-
ven, the cell-of-origin in BrafV600E-in-
duced PTC is in all probability the 
differentiated thyroid follicular cell. 
However, the earliest events in tumor 
initiation are yet unknown. To further 
elaborate this issue, we generated a Tg-
Cre;BrafCA/+;Rosa26mTmG/fl mouse line 
in which mutant Braf  and mTmG are 
conjointly expressed, thus labeling mu-
tant cells and the progeny for direct 
identification in the fluorescence mi-
croscope.
First, spontaneous activation of  Cre 
was studied in mice lacking BrafCA. This 
showed that a few mG+ cells were pre-
sent already before birth and that their 
numbers gradually increased until a 
majority of  the follicular cells expres-
sed GFP at 6 months of  age. However, 
postnatal follicles (P10) mostly contai-
ned single mG+ cells without signs of  
clonal expansion, indicating that Cre 
activation was stochastic.
In TgCre;BrafCA/+;Rosa26mTmG/fl mice, 
clonal expansion of  mG+ cells was 
evident already at one month of  age. 
Such mG+ clusters were increased in 
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number and size after 3-6 months and 
formed follicles in all instances. Even-
tually, they developed giant cyst-like 
structures limited by a monolayered 
epithelium that showed signs of  inward 
papillary projections.  To our knowled-
ge, this is the first demonstration of  
pre-tumorous, histoarchitectural alte-
rations induced by mutant Braf  in the 
thyroid in vivo. Occurrence of  single 
mG+ cells with abberant morphology 
suggestive of  OIS in high age mutant 
mice indicated differential susceptibili-
ty to oncogenic growth in the follicular 
cell population. The number of  mG+ 
cells markedly decreased in Braf  mu-
tant thyroids, suggesting spontaneous 
Cre activation was repressed and thus 
self-limiting to tracing.
Finally, the sporadic PTC model was 
tested in drug experiments, employing 
the tracing strategy to monitor early tu-
morigenesis. Animals with conditional 
Braf  activation in the absence of  ta-
moxifen were administered a diet with 
pellets containing the specific Braf  
inhibitor vemurafenib from weaning. 
Mutant littermates were put on a cor-
responding diet without vemurafenib. 
This showed that the thyroid size in 
treated animals was only 20 % of  the 
much enlarged glands encountered in 
untreated mutants. Also, much of  the 
morpohological changes induced by 
mutant Braf, were restored in treated 
animals. This experiment proves that 
BrafV600E is required and sufficient for 
thyroid tumor initiation.
Summar y of  results
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8 Discussion
”The more we are able to engage in 
enthusiastic disagreement with each other, 
the more we wil l  be able to uncover the best 
in ourselves and each other”
Karen Kimsey-House
(b. 1954)
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discussion
The first summarizing chapters have 
outlined the background for the studies 
that form the basis of  this thesis. The 
four papers included in the thesis pre-
sent the results from studies concerned 
with both embryonic development and 
tumor development. In this chapter, 
major findings will be briefly discussed 
in a broader context. For more detailed 
aspects, see individual papers.
8.1 FINDING CELL-OF-
ORIGIN OF THYROID 
C CELLS AND MTC
Mechanisms that govern embryonic 
development and tumor initiation in 
the thyroid are far from fully under-
stood. Knowing the origin of  cells is 
important since it might favor the un-
derstanding of  tumor development. 
Medullary thyroid cancer (MTC) is de-
rived from C cells and belongs to the 
group of  so-called neuroendocrine 
cancers. Since the origin of  C cells has 
never before been definitively explored 
in mammals, paper I provides impor-
tant insight by establishing the endo-
derm as the germ layer from which the 
C cells originate in mice. Since mice 
and humans share many developmen-
tal traits it is reasonable to assume that 
the same holds true for humans and 
probably the entire mammalian series. 
The expression of  forkhead box prote-
ins Foxa1 and Foxa2 showed a pattern 
in human MTC that is in accordance 
with the properties they seem to con-
fer in the embryonic thyroid regarding 
differentiation and growth. In view of  
numerous studies by others on the im-
portance of  these factors in both em-
bryonic development and tumor deve-
lopment (Khoor, Stahlman, Johnson, 
Olson, & Whitsett, 2004; Minoo et 
al., 2007; Song, Washington, & Craw-
ford, 2010), a differential expression of  
Foxa1 and Foxa2 as found in C cell pre-
cursors and MTC tumor cells probably 
reflects their roles in growth regulation 
and maintaining the epithelial phenoty-
pe. It is of  particular interest that they 
may execute a similar function in inva-
sion and metastatic spread. 
Differentiation of  thyroid C cells se-
emed to be spatiotemporally restricted 
during development with dedifferenti-
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ation prevailing connected to events in 
which migratory properties are needed 
for the dissemination of  C cells precur-
sors into the thyroid proper. MTC is a 
tumor form that is prone to metastatic 
spread, which is probably an inherent 
trait. This possibly reflects the develop-
mental course in which rearrangement 
of  E-cadherin-based adhesion and per-
sistent loss of  apical polarity, as obser-
ved in paper II, are prominent features 
of  the normal C cell phenotype. No-
tably, we observed that transient dedif-
ferentiation, of  MTC tumors, indicated 
by loss of  Foxa2 and calcitonin expres-
sion took place in invasive tumor cells 
that underwent EMT. Speculatively, 
the inborn ability to degrade basement 
membranes, as found in embryonic C 
cells emerging from the UBs, might 
be reactivated in MTC facilitating tu-
mor cell invasiveness. The expression 
of  calcitonin among normal cells is 
unique for thyroid C cells, and mea-
surement of  calcitonin blood levels is 
valuable as a biomarker in MTC (Bae, 
Schaab, & Kratzsch, 2015). However, 
calcitonin expression is only present in 
differentiated cells and the progression 
of  a tumor to a less differentiated state, 
associated with higher level of  aggres-
siveness is a plausible subject for conti-
nued studies.
Lineage tracing has provided powerful 
methods to investigate and determine 
the fate of  different cell populations 
during development (Kretzschmar & 
Watt, 2012). The origin of  C cells in 
endoderm explains several notions that 
were previously hard to understand. 
One of  them is that C cells have been 
found in some patient with DiGeorge 
syndrome, in which the fourth pha-
ryngeal pouches and consequently, the 
UBs do not form (Pueblitz, Weinberg, 
& Albores-Saavedra, 1993). Also in-
tringuingly, MTC has been found in the 
lingual thyroid of  a patient, in which no 
orthotopic thyroid was found (Yady, 
Singh, Singh, & Aggarwal, 2008). A 
shared endodermal origin of  the two 
cell lineages makes it more plausible 
that early progenitors might be potent 
of  developing into both cell types. 
Another important matter, on which 
the endodermal origin of  C cells could 
shed light, is the fact that mutations in 
the RET proto-oncogene are found in 
both PTC and MTC, while being rare 
in other tumor forms (Romei et al., 
2016). Also intriguingly, is the obser-
vation that there are cases of  mixed 
medullary-follicular thyroid carcinoma 
(MMFTC) present at higher rate than 
could be expected by random co-oc-
currence of  two independent cancers 
(Matias-Guiu, 1999; Ueki et al., 2011). 
A shared endodermal origin is compa-
tible with a susceptibility of  both cell 
types to transformation by the same 
oncogenic germ line mutation. Indeed, 
there are hereditary forms of  MTC, in 
which mixed tumors develop already in 
childhood, possibly from a stem cell, 
capable of  differentiation into both 
follicular and C cells (Goyal, Nada, Rao 
Katragadda, & Radotra Bishan, 2006; 
Kovacs Christopher, Masé Robert, 
Kovacs, Nguyen, & Chik Constance, 
2006; M. Nilsson & Williams, 2016). 
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There are some lessons to learn from 
the concept of  the neuroendocrine 
system, which emerged to describe 
endocrine tissues that were thought 
to have a shared embryonic origin in 
the neural crest. First, the results of  a 
study are always limited by the method 
employed, and the development of  
new techniques is constantly giving us 
previously unforeseen opportunities to 
study biological phenomena. The avian 
chimera model was seminal to investi-
gate the fate of  NCCs and rendered 
very important knowledge about em-
bryonic development, although some 
of  the conclusions from these studies 
now have proven faulty or at least not 
valid in mammals. Second, there is im-
portant cross-talk between different tis-
sues during development and without 
doubt, the NC provides important 
contributions, not only to the transient 
structure of  the pharyngeal apparatus, 
but also in the signaling network that 
is important also for regulating the 
development of  surrounding tissues. 
Understanding the migratory proper-
ties of  the NCCs could also aid in the 
search for mechanisms that govern the 
grade of  differentiation and proneness 
to invasiveness in transformed cells. 
Third, a concept that originally evolved 
based on an assumed shared embryo-
nic origin, might still be relevant in des-
cribing shared phenotypic characteris-
tics of  tissues and tumors derived from 
cells with distinct gene expression sig-
natures.
8.2 TUMOR INITIATION 
IN PTC
Cells of  the same lineage in a given tis-
sue are not all homogeneous. They dis-
play a heterogeneity regarding the level 
of  differentiation and growth-prone 
abilities that influence the cell phenoty-
pe and possibly the response to various 
stimuli, although the microenviron-
ment in which they reside is similar. 
However, to what extent if  any such 
heterogeneities may explain why the 
same oncogenic event and constituti-
ve activation of  identical intracellular 
signaling pathway confer development 
of  different tumor phenotypes is unk-
nown. In Papers III and IV, we charac-
terized the sporadic activation of  Cre 
in a mouse model of  BrafV600E-induced 
PTC. In most models that use the Cre/
loxP-system to achieve spatiotemporal 
control of  a genetic event, sporadic re-
combination in absence of  the inducing 
agent is considered to be a disadvanta-
ge. In our studies, we took advantage 
of  this ugly duckling. We discovered 
that this proved a unique possibility 
to study tumor development in an en-
vironment that is a closer mimic of  hu-
man PTC development than in previo-
us models, in which global activation 
of  an oncogenic mutation, no matter 
if  it is constitutively or induced, trans-
forms the entire thyroid gland with ge-
neral and profound effects on epithe-
lial morphology and hormone status. 
Our mice were euthyroid, ruling out 
the effect of  elevated TSH signaling as 
a growth-stimulating factor. We found 
that a plethora of  PTC histotypes de-
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veloped multifocally in the same gland 
over a considerable time period of  the 
mouse lifetime that may correspond to 
the natural course of  tumor develop-
ment in humans. Although additional 
genetic aberrations may occur explai-
ning differences in clonal growth cha-
racteristics, these studies provide the 
first insight in the evolution of  thyroid 
cancer from tumor initiation in the fol-
licular context to the development of  
overt, macroscopic tumors.
8.3 THE INSTRUMENTAL 
SPONTANEOUS 
ACTIVATION OF CRE
The spontaneous activation of  Cre in 
the absence of  induction by tamoxifen 
was investigated with the double-flu-
orescent reporter mTmG in Paper IV, 
and we were thus able to quantify the 
pace at which sporadic tumor initiation 
and development occurred. In the nor-
mal thyroid, we found that Cre activa-
tion started already at the embryonic 
stage E18.5, only three days after onset 
of  Tg expression. Gradually, more cells 
converted to the pool of  mG+ thyroid 
follicular cells. They mostly appeared as 
single green fluorescent cells although, 
rarely, mG+ cells neighboring each 
other were encountered. Since the thy-
roid is substantially enlarged postna-
tally due to follicular cell proliferation 
and new follicles are likely to be added 
to those already formed in embryonic 
development, the limited number of  
mG+ cell pairs appearing before the age 
of  one month suggested that recruit-
ment by cell division within the mG+ 
pool contributed little and that Cre was 
mostly activated stochastically. Impor-
tantly, this showed that sporadic Cre 
activity is a phenomenon that eventu-
ally encompasses a majority of  cells in 
the normal gland, but that individual 
mG+ cell are most often encountered 
with only mT+ neighbors. This allows 
the tracing of  individual mG+ proge-
nies and their clonal expansion upon a 
targeted growth stimulus.
By combining TgCre;Rosa26mTmG/fl mice 
with BrafCA mice, we were able to tra-
ce, for the first time, the destiny of  
oncogene-.activated, differentiated thy-
roid follicular cells in vivo in the natu-
ral microenvironment during postnatal 
thyroid growth and in the adult gland 
in which cell renewal normally is very 
slow (Coclet, Foureau, Ketelbant, Ga-
land, & Dumont J, 1989). Assuming the 
concept of  clonal growth from a single 
mutant cell, our studies clearly showed 
that Braf  mutant thyroid cells are able 
to form follicles by planar growth, thus 
indicating that both epithelial and fol-
licular integrity were preserved. This 
further showed that planar growth 
eventually leading to a highly convo-
luted follicular epithelium formed the 
basis of  papillary formations featuring 
the classical PTC variant.
We expected to find tumor growth only 
among mG+ cells. However, it was evi-
dent that also the mT+ epithelium ex-
hibited changes resembling of  tumor 
development. The definite answer to 
why this happened is still elusive and 
possible explanations are discussed in 
Paper IV. Without induced activation 
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of  a Cre driver and with a combination 
of  several floxed alleles, it is apparently 
crucially important to take into consi-
deration the possibility of  a stochastic 
pattern of  recombination events that 
not necessarily activates all transgenes 
simultaneously in the same cell. Also, 
down-regulation of  Tg and thus Cre 
expression by constitutive activation of  
the MAPK pathway opens for a self-li-
miting process that may hinder activa-
tion of  mTmG in Braf  mutant cells. 
The fact that mT+ neoplasias domina-
ted over mG+ tumors are in line with 
this possibility. 
Several existing mouse models use com-
binations of  floxed genes to study the 
effects of  multiple genetic events and 
their impact on tumor development. 
For example, inactivation of  the tumor 
suppressor gene TP53 has been shown 
to be important in the development of  
anaplastic thyroid cancer (ATC). In a 
mouse model similar to ours, activation 
of  BrafV600E in combination with inacti-
vated p53 led to progression from PTC 
to ATC (McFadden et al., 2014). Using 
a similar model without induction 
would be an attractive way to study also 
ATC in a more realistic way. However, 
the results from Paper IV shows that 
such a strategy needs to take into consi-
deration the fact that the desired mul-
tiple recombination events might not 
take place within the same cell. 
Regardless technical shortcomings, 
tumor lineage tracing in the sporadic 
model still provides important oppor-
tunities to study early events during tu-
mor development and the interactions 
between tumor-initiated cells and their 
microenvironment. Also, mutant cells 
that show signs of  OIS are readily de-
tectable by mTmG reporter activation, 
making it possible to identify and study 
their fate more closely.
9 Conclusions
”A hundred suspicions don’ t 
make a proof ”
Fyodor Dostoyevsky, in Crime and 
Punishment
(1821–1881)
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concLusions
The thesis work may be concluded around two themes based on cell-of-origin of  
thyroid cancer and their normal endocrine counterparts as follows:
 C cells – MTC
• Thyroid C cells originate in pharyngeal endoderm, rejecting the pre-
vious concept of a neural crest origin
• Degradation of laminin promotes C cell entry to the embryonic thy-
roid manufactured by a Nkx2-1 dependent mechanism in the ultimo-
branchial epithelium
• The pro-migratory properties of epithelial C cells are established 
during organogenesis by loss of apical polarity
• Foxa1 and Foxa2 likely exert different roles in promoting growth 
and differentiation of embryonic C cells
• Human medullary thyroid carcinoma cells differentially express 
Foxa1 and Fox2 in a way that correlates with tumor growth and inva-
sion
 Follicular cells – PTC
• Spontaneous activation of iTgCre recombinase in an inducible 
mouse model targeting BrafV600E to the thyroid, generates multifocal 
tumors in euthyroid mice
• This model confers sporadic development of papillary thyroid can-
cer subtypes in the normal thyroid microenvironment
• Tracing tumor initiation by the double-fluorescent reporter (mTmG) 
enables the study of early events in BrafV600E-induced thyroid cancer
• The sporadic thyroid cancer model is suitable for studies of targeted 
drug therapy 
10 Future perspectives
”There is no better boost in the present than 
an invitation into the future”
Caroline Kepnes
(b 1976)
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future perspectives
My work is by no means complete or 
finished. There are a lot of  possible 
ways to continue from the achieve-
ments so far. 
Regarding the tumor project invol-
ving mTmG it is vitally important to 
investigate the correlation between 
Braf  activation and color conversion. 
This involves understanding the kinetic 
mechanisms that affect Cre activation 
and the possibility of  a double recom-
bination in the same cell. Without un-
derstanding the extent to which Cre 
both enacts oncogenic activation and 
color conversion it its impossible to 
appreciate the direct effects of  the on-
cogene activation compared to the ef-
fects that tumor-initiated cells have on 
their environment. 
Regardless of  this, our non-induced 
mouse model of  PTC can be used to 
address a number of  interesting ques-
tions. It provides a platform for a di-
versity of  morphological and molecu-
lar investigations.
Specimens from animals in the Tg-
Cre;BrafCA;Rosa26mTmG/fl-model of  PTC 
could be immunostained with a blue 
fluorochrome. This allows for a num-
ber of  questions being addressed to a 
model in which monoclonal expansion 
of  Braf  mutant cells is available for in-
vestigation. For example immunostai-
ning for laminin would be a way to pin-
point the changes in BM distribution 
that are involved in invasiveness.
The possibility to take advantage of  
sporadic Cre activity could very well be 
used in other mouse models with leaki-
ness in the Cre driver. Careful characte-
rization of  the sporadic activity should 
be undertaken and if  combining seve-
ral floxed transgenes, the correlation 
between recombination events at the 
different alleles should be determined.
In the end, the most important outco-
me is improved treatment for patients 
with thyroid cancer. Hopefully our mo-
del can help both in finding ideas for 
new treatments and for evaluation of  
the efficacy of  drug candidates.
Ongoing work in our lab includes com-
bining the PTC model with conditional 
inactivation of  p53, which is expec-
ted to confer progression to ATC. As 
mentioned in the Discussion section, 
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this requires careful assessment of  the 
correlation between recombination 
events. Since we use the mTmG re-
porter, tumor tissue could be subjected 
to fluorescent-activated cell sorting to 
isolate different cell populations and 
analyze genetic profiles and expression 
patterns. 
Others that work with the Cre/
loxP-system could probably benefit 
from our approach to take advantage 
of  the spontaneous Cre leakiness in 
non-induced mice to elaborate tumor 
development in a more natural setting 
than provided by global oncogene ac-
tivation. 
There is still a lot of  work to be done!
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